onvo-10q_20170630.htm

0001564590-17-016946.txt : 20170809 0001564590-17-016946.hdr.sgml : 20170809 20170809160729 ACCESSION NUMBER: 0001564590-17-016946 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170809 DATE AS OF CHANGE: 20170809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORGANOVO HOLDINGS, INC. CENTRAL INDEX KEY: 0001497253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 271488943 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35996 FILM NUMBER: 171017913 BUSINESS ADDRESS: STREET 1: 6275 NANCY RIDGE DRIVE STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-9994 MAIL ADDRESS: STREET 1: 6275 NANCY RIDGE DRIVE STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: REAL ESTATE RESTORATION & RENTAL, INC. DATE OF NAME CHANGE: 20100722 10-Q 1 onvo-10q_20170630.htm 10-Q onvo-10q_20170630.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-35996

Organovo Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware		27-1488943
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

6275 Nancy Ridge Drive, Suite 110, San Diego, CA 92121		(858) 224-1000
(Address of principal executive offices and zip code)		(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☒

Non-accelerated filer	☐ (Do not check if a smaller reporting company)	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of July 31, 2017, a total of 106,123,048 shares of the registrant’s Common Stock, $0.001 par value, were outstanding.

ORGANOVO HOLDINGS, INC.

INDEX

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets as of June 30, 2017 (Unaudited) and March 31, 2017 (Audited)	3
	Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss for the Three Months Ended June 30, 2017 and 2016	4
	Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended June 30, 2017 and 2016	5
	Notes to Unaudited Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4.	Controls and Procedures	21
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosure	23
Item 5.	Other Information	23
Item 6.	Exhibits	24

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Organovo Holdings, Inc.

Condensed Consolidated Balance Sheets

(in thousands except for share data)

	June 30, 2017			March 31, 2017
	(Unaudited)			(Audited)
Assets
Current Assets
Cash and cash equivalents	$	54,974		$	62,751
Accounts receivable		772			647
Inventory, net		461			550
Prepaid expenses and other current assets		1,661			1,144
Total current assets		57,868			65,092
Fixed assets, net		3,528			3,840
Restricted cash		127			127
Other assets, net		189			121
Total assets	$	61,712		$	69,180
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable	$	558		$	1,171
Accrued expenses		2,111			4,101
Deferred rent		165			157
Deferred revenue		854			582
Total current liabilities		3,688			6,011
Deferred revenue, net of current portion		48			58
Deferred rent, net of current portion		707			749
Total liabilities		4,443			6,818
Commitments and Contingencies (Note 4)
Stockholders’ Equity
Common stock, $0.001 par value; 150,000,000 shares authorized, 105,724,320 and 104,551,466 shares issued and outstanding at June 30, 2017 and March 31, 2017, respectively		106			104
Additional paid-in capital		266,593			261,586
Accumulated deficit		(209,419	)		(199,317	)
Accumulated other comprehensive income (loss)		(11	)		(11	)
Total stockholders’ equity		57,269			62,362
Total Liabilities and Stockholders’ Equity	$	61,712		$	69,180

The accompanying notes are an integral part of these condensed consolidated financial statements.

Organovo Holdings, Inc.

Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss

(in thousands except share and per share data)

	Three Months Ended			Three Months Ended
	June 30, 2017			June 30, 2016
Revenues
Products and services	$	944		$	674
Collaborations and licenses		46			213
Grants		—			4
Total Revenues		990			891

Cost of revenues		301			168
Research and development expenses		5,033			4,444
Selling, general, and administrative expenses		5,856			5,056
Total costs and expenses		11,190			9,668
Loss from Operations		(10,200	)		(8,777	)
Other Income (Expense)
Change in fair value of warrant liabilities		—			(5	)
Interest income		98			37
Total Other Income (Expense)		98			32
Income Tax Expense		—			(22	)
Net Loss	$	(10,102	)	$	(8,767	)
Currency Translation Adjustment	$	(11	)	$	—
Comprehensive Loss	$	(10,113	)	$	(8,767	)
Net loss per common share—basic and diluted	$	(0.10	)	$	(0.09	)
Weighted average shares used in computing net loss per common share—basic and diluted		104,689,391			92,391,964

The accompanying notes are an integral part of these condensed consolidated financial statements.

Organovo Holdings, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

	Three Months Ended			Three Months Ended
	June 30, 2017			June 30, 2016
Cash Flows From Operating Activities
Net loss	$	(10,102	)	$	(8,767	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		326			251
Change in fair value of warrant liabilities		—			5
Stock-based compensation		2,052			1,429
Increase (decrease) in cash resulting from changes in:
Accounts receivable		(125	)		156
Inventory		89			(178	)
Prepaid expenses and other assets		(518	)		(41	)
Accounts payable		(613	)		(306	)
Accrued expenses		(1,990	)		(735	)
Deferred rent		(34	)		(36	)
Deferred revenue		262			(319	)
Net cash used in operating activities		(10,653	)		(8,541	)
Cash Flows From Investing Activities
Purchases of fixed assets		(11	)		(12	)
Purchases of intangible assets		(70	)		—
Net cash used in investing activities		(81	)		(12	)
Cash Flows From Financing Activities
Proceeds from issuance of common stock and exercise of warrants, net		2,957			—
Net cash provided by financing activities		2,957			—
Net Increase (Decrease) in Cash and Cash Equivalents		(7,777	)		(8,553	)
Cash and Cash Equivalents at Beginning of Period		62,751			62,091
Cash and Cash Equivalents at End of Period	$	54,974		$	53,538
Supplemental Disclosure of Cash Flow Information:
Interest paid	$	—		$	—
Income taxes paid	$	—		$	22

The accompanying notes are an integral part of these condensed consolidated financial statements.

Organovo Holdings, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

Note 1. Description of Business and Summary of Significant Accounting Policies

Nature of operations and basis of presentation

References in these notes to the unaudited condensed consolidated financial statements to “Organovo Holdings, Inc.,” “Organovo Holdings,” “we,” “us,” “our,” “the Company” and “our Company” refer to Organovo Holdings, Inc. and its consolidated subsidiaries. Our consolidated financial statements include the accounts of the Company as well as its wholly-owned subsidiaries, with all material intercompany accounts and transactions eliminated in consolidation. In December 2014, we established a wholly-owned subsidiary, Samsara Sciences, Inc., to focus on the acquisition of qualified cells in support of our commercial and research endeavors. In September 2015, we established another wholly-owned subsidiary in the United Kingdom, Organovo U.K., Ltd., for the primary purpose of establishing a sales presence in Europe.

Since its inception, the Company has devoted its efforts primarily to developing and commercializing a platform technology and functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company has also focused efforts on raising capital and building infrastructure. In November 2014, the Company announced the commercial release of its first product, the ExVive™ Human Liver Tissue for use in toxicology and other preclinical drug testing. In September 2016, the Company announced that it had begun commercial contracting for services relating to its second product, the ExVive™ Human Kidney tissue.

The Company’s activities are subject to significant risks and uncertainties including failing to successfully develop products and services based on its technology and to achieve the market acceptance necessary to generate sufficient revenues to support its operations and to achieve and sustain profitability.

The accompanying interim condensed consolidated financial statements have been prepared by the Company, without audit, in accordance with the instructions to Form 10-Q and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of its financial position, results of operations, stockholders’ equity and cash flows in accordance with generally accepted accounting principles (“GAAP”). The balance sheet at March 31, 2017 is derived from the Company’s audited balance sheet at that date.

In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These financial statements should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2017, filed with the Securities and Exchange Commission (the “SEC”) on June 7, 2017. Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2018.

Liquidity

As of June 30, 2017, the Company had cash and cash equivalents of approximately $55.0 million and an accumulated deficit of approximately $209.4 million. The Company also had negative cash flows from operations of approximately $10.7 million during the three months ended June 30, 2017.

Through June 30, 2017, the Company has financed its operations primarily through the sale of convertible notes, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative research agreements, grants, and licenses. During the quarter ended June 30, 2017, the Company issued 1,139,489 shares of its common stock through its ATM facility and received net proceeds of approximately $3.0 million.

On October 25, 2016, the Company closed the issuance and sale of 10,065,000 shares of its common stock in an underwritten public offering. The Company received net proceeds of approximately $25.7 million in the offering, after deducting underwriting discounts and commissions and the Company’s expenses. Based on its current operating plan and available cash resources, the Company has sufficient resources to fund its business for at least the next twelve months from the financial statement issuance date.

The Company will need additional capital to further fund the development and commercialization of its human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or diseased tissues and organs. The Company intends to cover its future operating expenses through cash on hand, through revenue derived from research service agreements, product sales, collaborative research agreements, grants and royalty payments, and through the issuance of additional equity or debt securities. Depending on market conditions, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders.

Having insufficient funds may require us to delay, scale back, or eliminate some or all of our development programs or relinquish rights to our technology on less favorable terms than we would otherwise choose. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

Use of estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the condensed consolidated financial statements include those assumed in revenue recognized under the proportional performance model, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets.

Fair value measurement

The Company had issued warrants, of which some were classified as derivative liabilities as a result of the terms in the warrants that provide for down-round protection in the event of a dilutive issuance. The Company used Level 3 inputs (unobservable inputs that are supported by little or no market activity, and that are significant to the fair value of the assets or liabilities) for its valuation methodology for the warrant derivative liabilities. The estimated fair values were determined using a Monte Carlo option pricing model based on various assumptions. The Company’s derivative liabilities were adjusted to reflect estimated fair value at each period end, with any increase or decrease in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of the derivative liabilities. Various factors are considered in the pricing models the Company used to value the warrants, including the Company’s current stock price, the remaining life of the warrant, the volatility of the Company’s stock price, and the risk-free interest rate. The remaining warrants expired as of March 31, 2017 and were removed from the Balance Sheet. The Company does not have any financial assets or liabilities measured on a fair value basis as of June 30, 2017 or March 31, 2017.

Revenue recognition

The Company’s revenues are derived from research service agreements, product sales, collaborative research agreements, grants and license- payments from the National Institutes of Health (“NIH”), U.S. Treasury Department, academic institutions, and private not-for-profit organizations.

The Company recognizes revenue when the following criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) services have been rendered or product has been delivered; (iii) price to the customer is fixed and determinable; and (iv) collection of the underlying receivable is reasonably assured.

Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of June 30, 2017 and March 31, 2017, the Company had approximately $903,000 and $640,000, respectively, in deferred revenue related to its grants and royalty payments, collaborative research programs and research service agreements.

Revenue arrangements with multiple deliverables

The Company follows ASC 605-25 Revenue Recognition – Multiple-Element Arrangements for revenue arrangements that contain multiple deliverables. Judgment is required to properly identify the accounting units of the multiple deliverable transactions and to determine the manner in which revenue should be allocated among the accounting units. Moreover, judgment is used in interpreting the commercial terms and determining when all criteria of revenue recognition have been met for each deliverable in order for revenue recognition to occur in the appropriate accounting period. For multiple deliverable agreements, consideration is allocated at the inception of the agreement to all deliverables based on their relative selling price. The relative selling price for each deliverable is determined using vendor-specific objective evidence (“VSOE”) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable.

While changes in the allocation of the arrangement consideration between the units of accounting will not affect the amount of total revenue recognized for a particular sales arrangement, any material changes in these allocations could impact the timing of revenue recognition, which could affect the Company’s results of operations.

The Company periodically receives license fees for non-exclusive research licensing associated with funded research projects. License fees under these arrangements are recognized over the term of the contract or development period as it has been determined that such licenses do not have stand-alone value.

Revenue from research service agreements

For research service agreements that contain only a single or primary deliverable, the Company defers any up-front fees collected from customers, and recognizes revenue for the delivered element only when it determines there are no uncertainties regarding customer acceptance. For agreements that contain multiple deliverables, the Company follows ASC 605-25 as described above.

Research and development revenue under collaborative agreements

The Company’s collaboration revenue consists of license and collaboration agreements that contain multiple elements, which may include non-refundable up-front fees, payments for reimbursement of third-party research costs, payments for ongoing research, payments associated with achieving specific development milestones and royalties based on specified percentages of net product sales, if any. The Company considers a variety of factors in determining the appropriate method of revenue recognition under these arrangements, such as whether the elements are separable, whether there are determinable fair values and whether there is a unique earnings process associated with each element of a contract.

The Company recognizes revenue from research funding under collaboration agreements when earned on a “proportional performance” basis as research services are provided or substantive milestones are achieved. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to us for the milestone (i) is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance, (ii) relates solely to our past performance and (iii) is reasonable relative to all of the other deliverables and payments within the arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the risks that must be overcome to achieve the milestone, the level of effort and investment required to achieve the milestone and whether any portion of the milestone consideration is related to future performance or deliverables.

The Company initially defers revenue for any amounts billed or payments received in advance of the services being performed, and recognizes revenue pursuant to the related pattern of performance, using the appropriate method of revenue recognition based on its analysis of the related contractual element(s).

In November 2014, the Company entered into a collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter at the university for the purpose of developing bioprinted tissues for surgical transplantation research. The Company has recorded $0 and $12,500 for the three months ended June 30, 2017 and 2016, respectively, in revenue related to this collaboration in recognition of the proportional performance achieved.

In April 2015, the Company entered into a research collaboration agreement with a third party to develop custom tissue models for fixed fees. Based on the proportional performance achieved under this agreement, no collaboration revenue was recorded for the three months ended June 30, 2017 or 2016.

Also in April 2015, the Company entered into a multi-year research agreement with a third party to develop multiple custom tissue models for use in drug development. Approximately $0 and $200,000 were recorded as revenue in recognition of the proportional performance achieved under this agreement during the three months ended June 30, 2017 and 2016, respectively.

In June 2016, the Company announced it had entered into another collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter at the university for the purpose of developing bioprinted tissues for skeletal disease research. The Company received an up-front payment in June 2016, which was initially been recorded as deferred revenue. Revenue of $17,000 and $0 has been recorded under this agreement during the three months ended June 30, 2017 and 2016, respectively.

In December 2016, the Company signed another collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter at the university for the purpose of developing an architecturally correct kidney for potential therapeutic applications. The Company received an up-front payment in January and March of 2017, which has been recorded as deferred revenue. Revenue of $10,000 has been recorded under this agreement for the three months ended June 30, 2017.

Product revenue

The Company recognizes product revenue at the time of shipment to the customer, provided all other revenue recognition criteria have been met.

As our commercial sales increase, we expect to establish a reserve for estimated product returns that will be recorded as a reduction to revenue. This reserve will be maintained to account for future return of products sold in the current period. The reserve will be reviewed quarterly and will be estimated based on an analysis of our historical experience related to product returns.

Grant revenue

During August 2013, the Company was awarded a research grant by a private, not-for-profit organization for up to $251,700, contingent on go/no-go decisions made by the grantor at the completion of each stage of research as outlined in the grant award. Revenues from the grant are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized when the Company incurs expenses that are related to the grant. Revenue recognized under this grant was approximately $0 and $4,000 for the three months ended June 30, 2017 and 2016, respectively. The Company has completed its obligations under this agreement as of June 30, 2017.

Cost of revenues

The Company reported $0.3 million and $0.2 million in cost of revenues for the three months ended June 30, 2017 and 2016, respectively. This captures our costs related to manufacturing and delivering our product and service revenue.

Net loss per share

Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three months ended June 30, 2017 and 2016, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive.

Common stock equivalents excluded from computing diluted net loss per share were approximately 16.0 million for the three months ended June 30, 2017, and 11.6 million for the three months ended June 30, 2016.

Note 2. Stockholders’ Equity

Stock-based compensation expense and valuation information

Stock-based compensation expense for all stock awards consists of the following (in thousands):

	Three Months Ended		Three Months Ended
	June 30, 2017		June 30, 2016
Research and development	$	331	$	408
General and administrative	$	1,721	$	1,021
Total	$	2,052	$	1,429

The total unrecognized compensation cost related to unvested stock option grants as of June 30, 2017 was approximately $11,430,000 and the weighted average period over which these grants are expected to vest is 2.53 years.

The total unrecognized compensation cost related to unvested restricted stock units as of June 30, 2017 was approximately $7,814,000, which will be recognized over a weighted average period of 3.40 years.

As of June 30, 2017, there was no unrecognized stock-based compensation expense for restricted stock awards.

The total unrecognized stock-based compensation cost related to unvested ESPP shares as of June 30, 2017 was approximately $21,500, which will be recognized over a period of two months.

The Company calculates the grant date fair value of all stock-based awards in determining the stock-based compensation expense. Stock-based awards include (i) stock options, (ii) restricted stock awards, (iii) restricted stock units, and (iv) rights to purchase stock under the 2016 Employee Stock Purchase Plan (“ESPP”).

The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

	Three Months Ended			Three Months Ended
	June 30, 2017			June 30, 2016
Dividend yield		—			—
Volatility		74.27	%		71.30	%
Risk-free interest rate		1.62	%		1.20	%
Expected life of options	6.00 years			6.00 years
Weighted average grant date fair value	$	1.79		$	2.03

The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Due to the Company’s limited historical data as an early-stage commercial business, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. Certain options granted to consultants are subject to variable accounting treatment and are required to be revalued until vested.

The fair value of each restricted stock award is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant.

The fair value of each restricted stock unit is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant.

The Company uses the Black-Scholes valuation model to calculate the fair value of shares issued pursuant to the Company’s ESPP. Stock-based compensation expense is recognized over the purchase period using the straight-line method. The fair value of ESPP shares was estimated at the purchase period commencement date using the following weighted average assumptions:

	Three Months Ended
	June 30, 2017
Dividend yield		—
Volatility		74.70	%
Risk-free interest rate		0.79	%
Expected term	6 months
Weighted average grant date fair value	$	1.04

Preferred stock

The Company is authorized to issue 25,000,000 shares of preferred stock. There are no shares of preferred stock currently outstanding, and the Company has no current plans to issue shares of preferred stock.

Common stock

In May 2008, the Board of Directors of the Company approved the 2008 Equity Incentive Plan (the “2008 Plan”). The 2008 Plan authorized the issuance of up to 1,521,584 common shares for awards of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock award units, and stock appreciation rights. The 2008 Plan terminates on July 1, 2018. No shares have been issued under the 2008 Plan since 2011, and the Company does not intend to issue any additional shares from the 2008 Plan in the future.

In January 2012, the Board of Directors of the Company approved the 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan authorized the issuance of up to 6,553,986 shares of common stock for awards of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance units, performance shares, and other stock or cash awards. The Board of Directors and stockholders of the Company approved an amendment to the 2012 Plan in August 2013 to increase the number of shares of common stock that may be issued under the 2012 Plan by 5,000,000 shares. In addition, the Board of Directors and stockholders of the Company approved an amendment to the 2012 Plan in August 2015 to further increase the number of shares of common stock that may be issued under the 2012 Plan by 6,000,000 shares, bringing the aggregate shares issuable under the 2012 Plan to 17,553,986. The 2012 Plan as amended and restated became effective on August 20, 2015 and terminates ten years after such date. As of June 30, 2017, 1,978,029 shares remain available for issuance under the 2012 Plan.

On April 24, 2017 the Company filed a Registration Statement on Form S-8 with the SEC authorizing the issuance of 2,297,034 shares of the Company’s common stock, pursuant to the terms of an Inducement Award Stock Option Agreement and an Inducement Award Performance-Based Restricted Stock Unit Agreement (collectively, the “Inducement Award Agreements”).

The Company filed a shelf registration statement on Form S-3 (File No. 333-189995), or the 2013 Shelf, with the SEC on July 17, 2013 authorizing the offer and sale in one or more offerings of up to $100,000,000 in aggregate of common stock, preferred stock, debt securities, or warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities. The 2013 Shelf was declared effective by the SEC on July 26, 2013 and subsequently expired in 2016.

A shelf registration statement on Form S-3 (File No. 333-202382), or the 2015 shelf, was filed with the SEC on February 27, 2015 authorizing the offer and sale in one or more offerings of up to $190,000,000 in aggregate of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities. The 2015 shelf was declared effective by the SEC on March 17, 2015.

In December 2014, the Company entered into an equity offering sales agreement, or the 2014 Sales Agreement, with an investment banking firm. Under the terms of the distribution agreement, the Company could offer and sell up to $30,000,000 of its shares of common stock, from time to time, through the investment bank in at-the-market offerings, as defined by the SEC, and pursuant to the 2013 Shelf.

On July 20, 2016, the Company filed a prospectus supplement to move the remaining $26.6 million of common stock that previously could have been sold pursuant to the 2014 Sales Agreement under the 2013 Shelf to the 2015 Shelf, which does not expire until March 17, 2018. On that same date, the Company filed a post-effective amendment to the 2013 Shelf de-registering all remaining securities that could have been offered by the Company pursuant to the 2013 Shelf. During the three months ended June 30, 2017 and 2016, the Company issued 1,139,489 and no shares of common stock, respectively, for proceeds of $3.0 million and $0, respectively, in at-the-market offerings under the 2014 Sales Agreement. As of June 30, 2017, the Company has sold an aggregate of 3,136,670 shares of common stock in at-the-market offerings under the 2014 Sales Agreement, with net proceeds of approximately $13.7 million. Based on sales through June 30, 2017, the Company can sell an additional $18.8 million of shares pursuant to the 2014 Sales Agreement under the 2015 Shelf. The Company intends to use the net proceeds raised through any at-the-market sales for general corporate purposes, including research and development, the commercialization of the Company’s products, general administrative expenses, and working capital and capital expenditures.

On June 23, 2015, the Company closed the public offering of 10,838,750 shares of its common stock (the “2015 Offering”), which included the full exercise of the underwriters’ over-allotment. The 2015 Offering was effected pursuant to an Underwriting Agreement (the “2015 Underwriting Agreement”), dated June 18, 2015, with Jefferies LLC and Piper Jaffray & Co. (the “Representatives”), acting as representatives of the underwriters named in the 2015 Underwriting Agreement. The price to the public in the 2015 Offering was $4.25 per share, and the Underwriters agreed to purchase the shares from the Company pursuant to the 2015 Underwriting Agreement at a price of $3.995 per share. The net proceeds to the Company from the 2015 Offering were approximately $43.1 million, after deducting underwriting discounts and commissions and expenses payable by the Company. The 2015 Offering was made pursuant to the 2015 Shelf.

On October 25, 2016, the Company closed the public offering of 10,065,000 shares (the “2016 Offering”) of its common stock, which included partial exercise of the underwriters’ over-allotment. The 2016 Offering was effected pursuant to an Underwriting Agreement (the “2016 Underwriting Agreement”), dated October 20, 2016, with Jefferies LLC (the “Representative”), acting as representative of the underwriters named in the 2016 Underwriting Agreement. The price to the public in the 2016 Offering was $2.75 per share, and the underwriters purchased the shares from the Company pursuant to the 2016 Underwriting Agreement at a price of $2.585 per share. The net proceeds to the Company from the 2016 Offering were approximately $25.7 million after deducting underwriting discounts and commissions and expenses payable by the Company. The 2016 Offering was made pursuant to the 2015 Shelf.

During the three months ended June 30, 2017 and 2016, the Company issued no shares of common stock upon the exercise of warrants.

During the three months ended June 30, 2017 and 2016, the Company issued no shares of common stock upon the exercise of stock options.

Restricted stock awards

During the three months ended June 30, 2017 and 2016, there were 0 and 2,259 shares of restricted stock, respectively, cancelled related to shares of common stock returned to the Company, at the option of the holders, to cover the tax liability related to the vesting of 0 and 6,250 restricted stock awards, respectively. Upon the return of the common stock, an equal number of stock options with immediate vesting were granted to the individuals at the vesting date market value strike price.

Restricted stock units

During the three months ended June 30, 2017, the Company issued restricted stock units for an aggregate of 1,862,078 shares of common stock to its employees and directors. These shares of common will be issued upon vesting of the restricted stock units. Vesting generally occurs (i) on the one-year anniversary of the grant date, (ii) quarterly over a three-year period, (iii) quarterly over a four-year period, (iv) over a four-year period, with 25% vesting on the one-year anniversary of the vesting commencement date and the remainder vesting ratably on a quarterly basis over the next twelve quarters, or (v) over a three-year period with 50% vesting on the two-year anniversary of the vesting commencement date and 50% vesting on the three-year anniversary of the vesting commencement date.

A summary of the Company’s restricted stock unit activity from March 31, 2017 through June 30, 2017 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2017		1,178,114		$	3.57
Granted		1,862,078		$	2.66
Vested		(36,221	)	$	3.85
Canceled / forfeited		(80,857	)	$	3.21
Unvested at June 30, 2017		2,923,114		$	3.00

On April 24, 2017, in connection with the appointment of a new CEO, the Company allocated 208,822 Performance-Based Restricted Stock Units outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of NASDAQ Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. The Board of Directors has not formally approved the vesting criteria for the Performance-Based Restricted Stock Units, therefore these are not considered granted for accounting purposes and no expense has been recognized for the three months ended June 30, 2017.

Stock options

Under the 2012 Plan, 18,600 and 416,640 stock options were issued during the three months ended June 30, 2017 and 2016, respectively, at various exercise prices based on the closing market price of the Company’s common stock on the date of the grant. The stock options generally vest (i) on the one-year anniversary of the grant date, (ii) quarterly over a three-year period, or (iii) over a four-year period with a quarter vesting on either the one year anniversary of employment or the one year anniversary of the vesting commencement date, and the remainder vesting ratably over the remaining 36 month terms. Stock options can also vest immediately at the grant date or vest after one full year.

On April 24, 2017, in connection with the appointment of a new CEO, the Company granted 2,088,212 stock options outside of the 2012 Plan. The Company intends for these to be “inducement grants” within the meaning of NASDAQ Marketplace Rule 5635(c)(4). While granted outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. These stock options vest over a four-year period with a quarter vesting on either the one year anniversary of employment or the one year anniversary of the vesting commencement date.

A summary of the Company’s stock option activity for the three months ended June 30, 2017 is as follows:

	Options Outstanding			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2017		10,956,201		$	4.63	$	4,876,437
Options granted		2,106,812		$	2.73	$	—
Options canceled / forfeited		(160,464	)	$	4.50	$	—
Options exercised		—		$	—	$	—
Outstanding at June 30, 2017		12,902,549		$	4.32	$	3,210,430
Vested and Exercisable at June 30, 2017		7,420,483		$	4.69	$	3,017,444

The weighted-average remaining contractual term of options exercisable and outstanding at June 30, 2017 was approximately 5.61 years.

Employee Stock Purchase Plan

In June 2016, our Board of Directors adopted, and in August 2016 stockholders subsequently approved, the 2016 Employee Stock Purchase Plan (“ESPP”). We reserved 1,500,000 shares of common stock for issuance thereunder. The ESPP permits employees after five months of service to purchase common stock through payroll deductions, limited to 15 percent of each employee’s compensation up to $25,000 or 10,000 shares per employee per year. Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period. The initial offering period commenced in September 2016. At June 30, 2017, there were 1,447,443 shares available for purchase under the ESPP.

Warrants

During the three months ended June 30, 2017 and June 30, 2016, there were no warrant exercises.

The following table summarizes warrant activity for the three months ended June 30, 2017:

	Warrants		Weighted- Average Exercise Price
Balance at March 31, 2017		221,370	$	7.16
Granted		—	$	—
Exercised		—	$	—
Cancelled		—	$	—
Balance at June 30, 2017		221,370	$	7.16

The warrants outstanding at June 30, 2017 are exercisable at prices between $2.28 and $7.62 per share, and have a weighted average remaining term of approximately 1.61 years.

Common stock reserved for future issuance

Common stock reserved for future issuance consisted of the following at June 30, 2017:

Common stock warrants outstanding			221,370
Common stock options outstanding under the 2008 Plan			622,192
Common stock options outstanding and reserved under the 2012 Plan			12,170,174
Common stock reserved under the 2016 Employee Stock Purchase Plan			1,447,443
Restricted stock units outstanding under the 2012 Plan			2,923,114
Common stock options outstanding and reserved under the Inducement Awards			2,088,212
Restricted stock units outstanding under the Inducement Awards			208,822
Total at June 30, 2017			19,681,327

Note 3. Commitments and Contingencies

Operating leases

The Company leases laboratory and office space in San Diego, California under three non-cancelable leases as described below.

Since July 2012, the Company has leased its main facilities at 6275 Nancy Ridge Drive, San Diego, California 92121. The lease, as amended in 2013, 2015 and 2016, consists of approximately 45,580 rentable square feet containing laboratory, clean room and office space. Monthly rental payments are currently approximately $120,000 per month with 3% annual escalators. The lease term for 14,685 of the total rentable square footage expires on December 15, 2018, with the remainder of the rentable square footage expiring on September 1, 2021 with the Company having an option to terminate this lease on or after September 1, 2019.

On January 9, 2015, the Company entered into an agreement to lease a second facility consisting of 5,803 rentable square feet of office and lab space located at 6310 Nancy Ridge Drive, San Diego, California 92121. The term of the lease is 36 months, beginning on February 1, 2015 and ending on January 31, 2018, with monthly rental payments of approximately $12,000 commencing on April 1, 2015. In addition, there are annual rent escalations of 3% on each 12-month anniversary of the lease commencement date.

In addition to these two leases, the Company leased a third facility from February 1, 2016 through January 31, 2017, consisting of 12,088 rentable square feet of office space located at 6166 Nancy Ridge Drive, San Diego, California 92121 with a monthly rent of $15,000.

The Company records rent expense on a straight-line basis over the life of the leases and records the excess of expense over the amounts paid as deferred rent. In addition, one of the leases provides for certain improvements made for the Company’s benefit to be funded by the landlord. Such costs, totaling approximately $518,000 to date, have been capitalized as fixed assets and included in deferred rent.

Rent expense was approximately $366,000 and $303,000 for the three months ended June 30, 2017 and 2016, respectively.

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2017, are as follows (in thousands):

Fiscal year ended March 31, 2018	$	1,196
Fiscal year ended March 31, 2019		1,465
Fiscal year ended March 31, 2020		1,073
Fiscal year ended March 31, 2021		1,104
Fiscal year ended March 31, 2022		468
Thereafter		—
Total	$	5,306

Legal Matters

In addition to commitments and obligations in the ordinary course of business, the Company may be subject, from time to time, to various claims and pending and potential legal actions arising out of the normal conduct of its business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against it may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability.

The Company regularly reviews contingencies to determine the adequacy of its accruals and related disclosures. During the period presented, the Company has not recorded any accrual for loss contingencies associated with such claims or legal proceedings; determined that an unfavorable outcome is probable or reasonably possible; or determined that the amount or range of any possible loss is reasonably estimable. However, the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against the Company in a reporting period, the Company’s consolidated financial statements for that reporting period could be materially adversely affected.

Note 4. Concentrations

Credit risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions primarily located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company has not experienced losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

The Company is also potentially subject to concentrations of credit risk in its revenues and accounts receivable. Because it is in the early commercial stage, the Company’s revenues to date have been derived from a relatively small number of customers and collaborators. However, the Company has not historically experienced any accounts receivable write-downs and management does not believe significant credit risk exists as of June 30, 2017.

Note 5. Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard was originally effective for public companies for annual reporting periods beginning after December 15, 2016, with no early application permitted. In August 2015, the FASB issued ASU No. 2015-14 that defers by one year the effective date for all entities, with application permitted as of the original effective date. The updated standard becomes effective for us on April 1, 2018, with early adoption permitted as of April 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that this update will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of this updated standard on our ongoing financial reporting. We do not have plans to adopt this standard prior to the effective date.

In February 2016, the FASB issued ASU 2016-02, Leases, which requires an entity to recognize lease assets and lease liabilities on the balance sheet for leases with terms of more than 12 months and to disclose key information about leasing arrangements. This new guidance is effective for us on April 1, 2019, with early adoption permitted in any interim or annual period. The Company is currently evaluating the impact that this guidance will have on its financial statements and related disclosures.

In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718), which requires an entity recognize excess tax benefits and deficiencies as income tax expense or benefit, the cash flows of which should be included as operating activity in the statement of cash flows. An entity is allowed to either continue accruing compensation cost based on expected forfeitures or to begin recognizing expense as forfeitures occur. In addition, an entity may withhold the maximum statutory tax, increasing the allowable cash settlement portion of awards. The cash paid by an employer when directly withholding shares for tax purposes should be included in the financing activity section of the statement of cash flows. This new guidance became effective for us on April 1, 2017. The requirements of ASU 2016-09 did not have a significant impact on our consolidated financial statements.

Note 6. Subsequent Events

During July 2017, the Company issued 398,728 shares of its common stock pursuant to its at-the-market (“ATM”) facility for net proceeds exceeding $1.0 million.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following management’s discussion and analysis of financial condition and results of operations should be read in conjunction with the Company’s historical consolidated financial statements and the related notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017. This discussion and analysis contains forward-looking statements, such as statements related to our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions such as “will,” “may,” “could,” “should,” or similar expressions, identify certain of these forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to risks and uncertainties, including those described in this Quarterly Report on Form 10-Q, as well as the risk factors disclosed in our Annual Report on the Form 10-K for the fiscal year ended March 31, 2017, filed with the Securities and Exchange Commission on June 7, 2017, that could cause our actual results or events to differ materially from those expressed or implied by such forward-looking statements. Except to the limited extent required by applicable law, the Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Quarterly Report.

Basis of Presentation

References in this section to “Organovo Holdings, Inc.,” “Organovo Holdings,” “we,” “us,” “our,” “the Company” and “our Company” refer to Organovo Holdings, Inc. and its consolidated subsidiaries.

On February 8, 2012, Organovo, Inc., a privately held Delaware corporation, merged with and into Organovo Acquisition Corp., a wholly-owned subsidiary of the Company, with Organovo, Inc. surviving the merger as a wholly-owned subsidiary of the Company (the “Merger”). As a result of the Merger, the Company acquired and has continued the business of Organovo, Inc..

Organovo, Inc. was founded in Delaware in April 2007. Activities since Organovo, Inc.’s inception through June 30, 2017 have been devoted primarily to technology and product development, raising capital and building infrastructure.

In January 2016, we announced that our wholly-owned subsidiary, Samsara, commenced commercial operations. We formed Samsara to serve as a key source of certain of the primary human cells that we utilize in our products and services and in the development of therapeutic products. In addition to serving as one of our key suppliers, Samsara offers human cells for research use by life science customers, both directly and through distribution partners.

In addition, in September 2015, we established a wholly-owned subsidiary, Organovo UK, Ltd., to establish a sales presence in Europe. As of June 30, 2017, there has been no significant activity related to this subsidiary.

The condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the Securities and Exchange Commission (the “SEC”) instructions to Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements presented elsewhere in this Form 10-Q and discussed below are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (“GAAP”) to be included in a full set of financial statements. The audited financial statements for the year ended March 31, 2017, filed with the SEC on Form 10-K on June 7, 2017 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.

Overview

We are an early commercial stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or diseased tissues and organs. We are advancing a paradigm shift in the generation of three-dimensional (“3D”) human tissues, by utilizing our proprietary platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. We leverage our unique 3D human tissue models to improve the current industry standard cell-based and animal model testing approaches to drug discovery and development by creating 3D tissues constructed solely of human cells. We believe our foundational approach to the 3D printing of living tissues, as disclosed in peer-reviewed scientific publications, and the continuous evolution of our core bioengineering technology platform combine to provide us with the opportunity to fill many critical gaps in commercially available preclinical human tissue modeling and tissue transplantation.

In November 2014, we announced the commercial release of our first product, the ExVive™ Human Liver Tissue for use in toxicology and other preclinical drug testing. Initial revenues derived from the product have been and will continue to be predominantly through our fee-based research service model, which involves testing compounds provided to us for analysis by our customers. Prior to initiating the service, our technical staff assists customers in determining the extent of testing to be conducted utilizing our ExVive™ Human Liver Tissue. Testing may include the analysis of one or multiple compounds under various dosing and duration protocols to determine toxicity, metabolic and other effects of the test compounds on healthy or diseased tissue models. Projects may involve multiple deliverables which are clearly defined and based on pricing as stated in the related customer agreements.

In September 2016, we began commercial contracting for our second tissue service, the ExVive™ Human Kidney Tissue. This kidney proximal tubule model is a natural expansion of our preclinical product and service portfolio, allowing customers to study the effects of drug exposure on a key portion of the human kidney relevant to drug discovery and development.

In addition to our ExVive™ Human Liver Tissue and ExVive™ Human Kidney Tissue, we have entered into collaborative research agreements with pharmaceutical corporations and academic medical centers to develop new tissue models. We have also secured federal grants, including National Institute of Health grants, to support the development of our technology.

In October 2016, we announced our plan to develop 3D bioprinted human liver tissue for direct transplantation to patients. Our program to develop this therapeutic tissue is based on the achievement of promising results in early preclinical animal studies demonstrating engraftment, vascularization and sustained functionality of our bioprinted liver tissue, including stable detection of human liver-specific proteins and metabolic enzymes. We are pursuing this opportunity with a formal preclinical development program.

We continuously engage in research and development to enhance our platform technology, to develop new product and service offerings and to pursue our therapeutic initiatives. Our research and development efforts include internal initiatives as well as collaborative development opportunities with third parties.

Critical Accounting Policies, Estimates, and Judgments

Our financial statements are prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We continually evaluate our estimates and judgments, the most critical of which are those related to revenue recognition, valuation of long-lived assets and warrant liability, stock-based compensation and the timing of the achievement of collaboration milestones. We base our estimates and judgments on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. Besides the estimates identified above that are considered critical, we make many other accounting estimates in preparing our financial statements and related disclosures. All estimates, whether or not deemed critical, affect reported amounts of assets, liabilities, revenues and expenses, as well as disclosures of contingent assets and liabilities. These estimates and judgments are also based on historical experience and other factors that are believed to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known, even for estimates and judgments that are not deemed critical.

For further information, refer to the Company’s audited financial statements and notes thereto included in the Annual Report on Form 10-K for the year ended March 31, 2017, filed with the SEC on June 7, 2017.

Results of Operations

Comparison of the three months ended June 30, 2017 and 2016

Revenues

For the three months ended June 30, 2017, total revenue of $1.0 million was $0.1 million, or approximately 10%, higher than total revenue for the three months ended June 30, 2016. Product and service revenue of approximately $0.9 million for the first quarter of fiscal 2018 increased 29% over product and service revenue of approximately $0.7 million in the first quarter of fiscal 2017. This increase was primarily driven by a gain in contracts for our liver tissue research services and sales of primary human cell and tissue products by our Samsara Sciences subsidiary. Collaboration revenue decreased $0.2 million as compared to the first quarter of fiscal 2017. This difference in the periods reflects the revenue recorded during the first fiscal quarter of 2017 related to the achievement of milestones under a collaboration agreement with a pharmaceutical company.

Costs and Expenses

Cost of Revenues

Cost of product and service revenues, which reflects expenses related to manufacturing our products and delivering services was $0.3 million for the three months ended June 30, 2017, compared to $0.2 million for the three months ended June 30, 2016. The increase was primarily due to increased product and service revenues over the prior year period.

Research and Development Expenses

Research and development expenses were approximately $5.0 million, an increase of $0.6 million, or 14%, from the prior year period. The increase was primarily due to increases in lab materials expense of approximately $0.3 million, facility expense increases of approximately $0.2 million, and a $0.1 million increase in staffing expense due to the increase in full-time research and development staff from an average of eighty full-time employees for the three months ended June 30, 2016 to an average of eighty-two full-time employees for the three months ended June 30, 2017.

Selling, General and Administrative Expenses

For the three months ended June 30, 2017, selling, general and administrative expenses were approximately $5.9 million, an increase of $0.8 million, or 16%, over the prior year period. This increase was largely due to an increase in share-based compensation expense over the prior year period of $0.7 million. In addition, there was a $0.3 million increase in other staffing costs as the Company increased its average selling, general and administrative headcount from thirty-four full-time employees in the first quarter of fiscal 2017 to thirty-seven full-time employees for the first quarter of fiscal 2018, to provide strategic infrastructure in developing collaborative relationships and commercializing research-derived product introductions. These increases were partially offset by a $0.1 million reduction in other corporate expenses compared to the prior year period.

Other Income (Expense)

Other income was approximately $0.1 million for the three months ended June 30, 2017, and consisted primarily of interest income. For the three months ended June 30, 2016, other income of less than $0.1 million consisted primarily of interest income. Interest income increased from the same period of fiscal 2017 due to higher average yields on short-term investment balances.

Financial Condition, Liquidity and Capital Resources

The Company has primarily devoted its efforts to technology and product development, raising capital and building infrastructure. In November 2014, the Company announced the full commercial release of its first product, the ExVive™ Human Liver Tissue for use in toxicology and other preclinical drug testing, and in September 2016, the Company began commercial contracting for our second tissue service, the ExVive™ Human Kidney Tissue. The Company has built a sales and marketing and research and development infrastructure to support the commercialization of research services for the ExVive™ Human Liver Tissue and the ExVive™ Human Kidney Tissue.

As of June 30, 2017, the Company had cash and cash equivalents of approximately $55.0 million and an accumulated deficit of $209.4 million. The Company also had negative cash flow from operations of $10.7 million during the three months ended June 30, 2017. At March 31, 2017, the Company had cash and cash equivalents of approximately $62.8 million and an accumulated deficit of $199.3 million.

At June 30, 2017, the Company had total current assets of approximately $57.9 million and current liabilities of approximately $3.7 million, resulting in working capital of $54.2 million. At March 31, 2017, the Company had total current assets of approximately $65.1 million and current liabilities of approximately $6.0 million, resulting in working capital of $59.1 million.

Net cash used by operating activities for the three months ended June 30, 2017 was approximately $10.7 million as compared to $8.5 million used in operating activities for the three months ended June 30, 2016. This $2.2 million increase in cash usage can be attributed primarily to a $1.4 million increase in operating expenses and working capital timing differences.

Net cash used in investing activities was approximately $0.1 million and less than $0.1 million for the three months ended June 30, 2017 and 2016, respectively. This increase can be attributed to investing in patent related intangible assets during the three months ended June 30, 2017.

Net cash provided by financing activities was approximately $3.0 million during the three months ended June 30, 2017 due primarily to the net proceeds raised from the sale of common stock in “at-the-market” offerings. No cash was provided by financing activities during the three months ended June 30, 2016. The Company intends to use these net proceeds for general corporate purposes, including research and development, the commercialization of our products, general administrative expenses, and working capital and capital expenditures.

Through June 30, 2017, we have financed our operations primarily through the sale of convertible notes, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and from revenue derived from grants and royalty payments, collaborative research agreements, product sales and research-based services. Based on our current operating plan and available cash resources, we have sufficient resources to fund our ongoing operations as currently planned for at least the next twelve months from the financial statement issuance date.

Our future capital needs will depend on the revenues we generate through our commercialization efforts and the resources we elect to spend to pursue our product development efforts and implement our business plan. As a result, we cannot predict with certainty when we may be required or otherwise elect to secure additional capital to fund our future operations and business plans.

We intend to cover our future operating expenses through cash on hand, revenue derived from research service agreements, product sales, grants and royalty payments, and collaborative research agreements and through the issuance of additional equity or debt securities. Depending on market conditions, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders.

The Company has an effective shelf registration statement on Form S-3 (File No. 333-202382), or the 2015 Shelf, that expires on March 17, 2018. As of June 30, 2017, the Company is authorized to offer and sell under the 2015 Shelf, in one or more offerings, common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units compromised one or more of the other securities. On July 20, 2016, the Company filed a prospectus supplement to the 2015 Shelf to move from an expiring shelf registration statement the remaining $26.6 million of common stock that previously could have been sold in ATM offerings pursuant to an equity offering sales agreement it had entered into with an investment banking firm in December 2014. During the three months ended June 30, 2017, the Company sold 1,139,489 shares of common stock in ATM offerings, with net proceeds of approximately $3.0 million, leaving an additional $18.8 million that can be raised through this ATM program.

Based on its use of the 2015 Shelf through June 30, 2017, the Company can offer an aggregate of $108.5 million in future offerings under the 2015 Shelf, including its ATM program.

As of June 30, 2017, the Company had 105,724,320 total issued and outstanding shares of common stock, and five-year warrants for the opportunity to purchase an additional 221,370 shares of common stock at exercise prices between $2.28 and $7.62 per share.

In addition, the Company’s 2008 Equity Incentive Plan provides for the issuance of up to 896,256 shares of its outstanding common stock and the 2012 Equity Incentive Plan, as amended, provides for the issuance of up to 17,553,986 shares of its common stock, to executive officers, directors, advisory board members, employees and consultants. The Company has also issued time-based and performance-based inducement awards for up to 2,297,034 shares of its common stock. Additionally, 1,500,000 shares of common stock have been reserved for issuance under the 2016 Employee Stock Purchase Plan. In aggregate, issued and outstanding common stock, shares underlying outstanding warrants, and shares issuable under outstanding equity awards or reserved for future issuance under the 2008 and 2012 Equity Incentive Plans and the 2016 Employee Stock Purchase Plan total 125,405,647 shares of common stock as of June 30, 2017.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements, including unrecorded derivative instruments that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We have certain warrants and options outstanding but we do not expect to receive sufficient proceeds from the exercise of these instruments unless and until the underlying securities are registered, and/or all restrictions on trading, if any, are removed, and in either case the trading price of our common stock is significantly greater than the applicable exercise prices of the options and warrants.

Effect of Inflation and Changes in Prices

Management does not believe that inflation and changes in price will have a material effect on the Company’s operations.

Contractual Obligations

In the normal course of business, we enter into contracts and commitments that obligate us to make payments in the future. The table below sets forth our significant contractual obligations and related scheduled payments as of June 30, 2017 (in thousands):

	Total		2018		2019 to 2020		2021 to 2022		2023 and thereafter
Operating lease obligations (A)	$	5,306	$	1,582	$	2,424	$	1,300	$	—
Total	$	5,306	$	1,582	$	2,424	$	1,300	$	—

(A)	Operating lease obligations are primarily comprised of remaining payments due under the Company’s facility leases.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The primary objective of our investment activities is to preserve our capital for the purpose of funding our operations. To achieve these objectives, our investment policy allows us to maintain a portfolio of cash, cash equivalents, and short-term investments in a variety of securities, including money market funds. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the majority of our investments are comprised of cash and cash equivalents. We currently do not hedge interest rate exposure. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure. We have limited foreign currency risk exposure as our business operates primarily in U.S. dollars. We do not have any significant foreign currency or other derivative financial instruments.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the quarterly period covered by this report were designed and operating effectively.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and our Chief Financial Officer, do not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 4 of the Notes to the Unaudited Condensed Consolidated Financial Statements within this Form 10-Q for a discussion of our legal proceedings and contingencies.

ITEM 1A. RISK FACTORS

In evaluating the Company and an investment in our common stock, we urge you to carefully consider the risks and other information in this Quarterly Report on Form 10-Q as well as the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017, filed with the Securities and Exchange Commission on June 7, 2017. There have been no material changes from the risk factors as previously disclosed in our Annual Report on Form 10-K. Any of the risks discussed in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations or financial condition.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The following exhibit index shows those exhibits filed with this report and those incorporated herein by reference:

Exhibit No.		Description

2.1		Agreement and Plan of Merger and Reorganization, dated as of February 8, 2012, by and among Organovo Holdings, Inc. a Delaware corporation, Organovo Acquisition Corp., a Delaware corporation and Organovo, Inc., a Delaware corporation (incorporated by reference from Exhibit 2.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on February 13, 2012)

2.2		Certificate of Merger as filed with the Delaware Secretary of State effective February 8, 2012 (incorporated by reference from Exhibit 2.2 to the Company’s Current Report on Form 8-K, as filed with the SEC on February 13, 2012)

2.3		Articles of Merger as filed with the Nevada Secretary of State effective December 28, 2011 (incorporated by reference from Exhibit 2.1 to the Company’s Current Report on Form 8-K, as filed with the Securities and Exchange Commission (the “SEC”) on February 3, 2012 (the “February 2012 Form 8-K”)

2.4		Agreement and Plan of Merger, dated as of December 28, 2011, by and between Real Estate Restoration and Rental, Inc. and Organovo Holdings, Inc. (incorporated by reference from Exhibit 2.2 to the Company’s Current Report on Form 8-K, as filed with the SEC on January 4, 2012)

2.5		Certificate of Merger as filed with the Delaware Secretary of State effective January 30, 2012 (incorporated by reference from Exhibit 2.3 to the February 2012 Form 8-K)

2.6		Agreement and Plan of Merger, dated as of January 30, 2012, by and between Organovo Holdings, Inc. (Nevada) and Organovo Holdings, Inc. (Delaware) (incorporated by reference from Exhibit 2.2 to the February 2012 Form 8-K)

2.7		Articles of Merger as filed with the Nevada Secretary of State effective January 30, 2012 (incorporated by reference from Exhibit 2.4 to the February 2012 Form 8-K)

3.1		Certificate of Incorporation of Organovo Holdings, Inc. (Delaware) (incorporated by reference from Exhibit 3.1 to the February 2012 Form 8-K)

3.2		Bylaws of Organovo Holdings, Inc. (Delaware) (incorporated by reference from Exhibit 3.2 to the February 2012 Form 8-K)

4.1		Form of Bridge Warrant of Organovo, Inc. (incorporated by reference from Exhibit 4.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on February 13, 2012)

4.2		Form of Warrant of Organovo Holdings, Inc. ($1.00 exercise price) issued to Placement Agent (incorporated by reference from Exhibit 4.2(i) to the Company’s Current Report on Form 8-K, as filed with the SEC on March 19, 2012)

4.3		Form of Warrant of Organovo Holdings, Inc. ($1.00 exercise price) issued to Placement Agent in exchange for Organovo, Inc. warrant issued to Selling Agent (incorporated by reference from Exhibit 4.2(iii) to the Company’s Current Report on Form 8-K, as filed with the SEC on March 19, 2012)

31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

31.2		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1		Certification pursuant to 18 U.S.C. Section 1350.*

101		Interactive Data File*

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ORGANOVO HOLDINGS, INC.

Date: August 9, 2017	By:	/s/ Taylor Crouch
	Name:	Taylor Crouch
	Title:	Chief Executive Officer and President (Principal Executive Officer)


Date: August 9, 2017	By:	/s/ Craig Kussman
	Name:	Craig Kussman
	Title:	Chief Financial Officer (Principal Financial Officer)

EX-31.1 2 onvo-ex311_6.htm EX-31.1 onvo-ex311_6.htm

Exhibit 31.1

CERTIFICATION

I, Taylor Crouch, Chief Executive Officer and President of Organovo Holdings, Inc. (the “Registrant”), certify that:

1. I have reviewed this quarterly report on Form 10-Q of the Registrant;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting

Dated: August 9, 2017

/s/ Taylor Crouch

Taylor Crouch

Chief Executive Officer and President

(Principal Executive Officer)

EX-31.2 3 onvo-ex312_7.htm EX-31.2 onvo-ex312_7.htm

Exhibit 31.2

CERTIFICATION

I, Craig Kussman, Chief Financial Officer of Organovo Holdings, Inc. (the “Registrant”), certify that:

1. I have reviewed this quarterly report on Form 10-Q of the Registrant;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting

Dated: August 9, 2017

/s/ Craig Kussman

Craig Kussman

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 onvo-ex321_8.htm EX-32.1 onvo-ex321_8.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Organovo Holdings, Inc. (the “Company”) for the period ended June 30, 2017, as filed with the Securities and Exchange Commission (the “Report”), I, Taylor Crouch, Chief Executive Officer and President and I, Craig Kussman, Chief Financial Officer of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

•

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

•

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2017

/s/ Taylor Crouch

Taylor Crouch

Chief Executive Officer and President

(Principal Executive Officer)

/s/ Craig Kussman

Craig Kussman

Chief Financial Officer

(Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to Organovo Holdings, Inc. and will be retained by Organovo Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission, and is not to be incorporated by reference into any filing of Organovo Holdings, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 onvo-20170630.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure onvo:Lease utr:sqft 0001497253 2017-04-01 2017-06-30 0001497253 2017-07-31 0001497253 2017-06-30 0001497253 2017-03-31 0001497253 2016-12-31 0001497253 2016-03-31 0001497253 2016-04-01 2016-06-30 0001497253 2016-06-30 0001497253 onvo:AtTheMarketFacilityMember 2017-06-30 0001497253 onvo:AtTheMarketFacilityMember 2017-04-01 2017-06-30 0001497253 onvo:TwoThousandSixteenUnderwritingAgreementMember us-gaap:OverAllotmentOptionMember 2016-10-25 0001497253 onvo:TwoThousandSixteenUnderwritingAgreementMember onvo:SecondaryOfferingMember 2016-10-23 2016-10-25 0001497253 us-gaap:ResearchAndDevelopmentArrangementMember 2017-06-30 0001497253 us-gaap:ResearchAndDevelopmentArrangementMember 2017-03-31 0001497253 onvo:ResearchAndDevelopmentArrangementSixMember 2017-04-01 2017-06-30 0001497253 onvo:ResearchAndDevelopmentArrangementSixMember 2016-04-01 2016-06-30 0001497253 onvo:ResearchAndDevelopmentArrangementFourMember 2017-04-01 2017-06-30 0001497253 onvo:ResearchAndDevelopmentArrangementFourMember 2016-04-01 2016-06-30 0001497253 onvo:ResearchAndDevelopmentArrangementFiveMember 2017-04-01 2017-06-30 0001497253 onvo:ResearchAndDevelopmentArrangementFiveMember 2016-04-01 2016-06-30 0001497253 onvo:ResearchAndDevelopmentArrangementSevenMember 2017-04-01 2017-06-30 0001497253 onvo:ResearchAndDevelopmentArrangementSevenMember 2016-04-01 2016-06-30 0001497253 onvo:ResearchAndDevelopmentArrangementEightMember 2017-04-01 2017-06-30 0001497253 onvo:PrivateMember us-gaap:MaximumMember 2013-08-01 2013-08-31 0001497253 onvo:PrivateMember 2017-04-01 2017-06-30 0001497253 onvo:PrivateMember 2016-04-01 2016-06-30 0001497253 us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001497253 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001497253 us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-06-30 0001497253 us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001497253 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0001497253 us-gaap:RestrictedStockUnitsRSUMember 2017-06-30 0001497253 us-gaap:RestrictedStockUnitsRSUMember 2017-04-01 2017-06-30 0001497253 us-gaap:RestrictedStockMember 2017-06-30 0001497253 onvo:EmployeeStockPurchasePlanMember 2017-06-30 0001497253 onvo:EmployeeStockPurchasePlanMember 2017-04-01 2017-06-30 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember 2017-04-01 2017-06-30 0001497253 onvo:EquityIncentivePlanTwoThousandEightMember 2008-05-31 0001497253 onvo:EquityIncentivePlanTwoThousandEightMember 2017-04-01 2017-06-30 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember 2012-01-31 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember 2013-08-31 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember 2015-08-31 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember 2017-06-30 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember 2017-04-01 2017-06-30 0001497253 onvo:InducementAwardAgreementsMember 2017-04-24 0001497253 us-gaap:IPOMember 2013-07-17 0001497253 us-gaap:IPOMember 2013-07-16 2013-07-17 0001497253 us-gaap:IPOMember 2015-02-27 0001497253 us-gaap:MaximumMember onvo:EquityDistributionAgreementMember 2014-12-01 2014-12-31 0001497253 onvo:EquityOfferingSalesAgreementMember 2016-07-20 0001497253 onvo:EquityOfferingSalesAgreementMember 2016-07-19 2016-07-20 0001497253 onvo:EquityOfferingSalesAgreementMember 2017-04-01 2017-06-30 0001497253 onvo:EquityOfferingSalesAgreementMember 2016-04-01 2016-06-30 0001497253 onvo:EquityOfferingSalesAgreementMember 2017-06-30 0001497253 onvo:EquityOfferingSalesAgreementMember 2014-12-01 2017-06-30 0001497253 onvo:SecondaryOfferingMember onvo:TwoThousandFifteenUnderwritingAgreementMember 2015-06-22 2015-06-23 0001497253 onvo:SecondaryOfferingMember onvo:TwoThousandFifteenUnderwritingAgreementMember 2015-06-23 0001497253 us-gaap:OverAllotmentOptionMember onvo:TwoThousandFifteenUnderwritingAgreementMember 2015-06-23 0001497253 onvo:TwoThousandSixteenUnderwritingAgreementMember onvo:SecondaryOfferingMember 2016-10-20 0001497253 onvo:TwoThousandSixteenUnderwritingAgreementMember us-gaap:OverAllotmentOptionMember 2016-10-20 0001497253 onvo:TwoThousandSixteenUnderwritingAgreementMember onvo:SecondaryOfferingMember 2016-10-19 2016-10-20 0001497253 us-gaap:RestrictedStockMember 2017-04-01 2017-06-30 0001497253 us-gaap:RestrictedStockMember 2016-04-01 2016-06-30 0001497253 us-gaap:RestrictedStockUnitsRSUMember onvo:ShareBasedCompensationAwardYearlyVestingMember 2017-04-01 2017-06-30 0001497253 us-gaap:RestrictedStockUnitsRSUMember 2017-03-31 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ChiefExecutiveOfficerMember 2017-04-24 0001497253 onvo:InducementAwardPerformanceBasedRestrictedStockUnitsMember us-gaap:ChiefExecutiveOfficerMember 2017-04-01 2017-06-30 0001497253 onvo:TwoThousandTwelvePlanMember 2017-04-01 2017-06-30 0001497253 onvo:TwoThousandTwelvePlanMember 2016-04-01 2016-06-30 0001497253 us-gaap:EmployeeStockOptionMember onvo:TwoThousandTwelvePlanMember 2017-04-01 2017-06-30 0001497253 onvo:InducementAwardAgreementsMember us-gaap:ChiefExecutiveOfficerMember 2017-04-23 2017-04-24 0001497253 us-gaap:EmployeeStockOptionMember onvo:InducementAwardAgreementsMember us-gaap:ChiefExecutiveOfficerMember 2017-04-23 2017-04-24 0001497253 us-gaap:EmployeeStockOptionMember onvo:InducementAwardAgreementsMember us-gaap:ChiefExecutiveOfficerMember 2017-04-01 2017-06-30 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember 2017-06-30 0001497253 us-gaap:WarrantMember 2017-04-01 2017-06-30 0001497253 us-gaap:WarrantMember 2016-04-01 2016-06-30 0001497253 us-gaap:WarrantMember 2017-03-31 0001497253 us-gaap:WarrantMember 2017-06-30 0001497253 us-gaap:MinimumMember 2017-06-30 0001497253 us-gaap:MaximumMember 2017-06-30 0001497253 onvo:EquityIncentivePlanTwoThousandEightMember us-gaap:EmployeeStockOptionMember 2017-06-30 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember us-gaap:EmployeeStockOptionMember 2017-06-30 0001497253 onvo:EmployeeStockPurchasePlanTwoThousandSixteenMember us-gaap:EmployeeStockOptionMember 2017-06-30 0001497253 onvo:EquityIncentivePlanTwoThousandTwelveMember us-gaap:RestrictedStockUnitsRSUMember 2017-06-30 0001497253 onvo:InducementAwardAgreementsMember us-gaap:EmployeeStockOptionMember 2017-06-30 0001497253 onvo:InducementAwardAgreementsMember us-gaap:RestrictedStockUnitsRSUMember 2017-06-30 0001497253 onvo:LeaseTermForFourteenThousandSixHundredAndEightyFiveOfRentableSquareFootageMember 2017-04-01 2017-06-30 0001497253 onvo:LeaseTermForRemainderOfRentableSquareFootageMember 2017-04-01 2017-06-30 0001497253 2015-01-09 0001497253 2015-01-08 2015-01-09 0001497253 2015-12-28 0001497253 2015-12-27 2015-12-28 0001497253 2012-07-01 2017-06-30 0001497253 us-gaap:SubsequentEventMember onvo:AtTheMarketFacilityMember 2017-07-31 0001497253 us-gaap:SubsequentEventMember onvo:AtTheMarketFacilityMember us-gaap:MinimumMember 2017-07-01 2017-07-31 10-Q false 2017-06-30 2018 Q1 ONVO ORGANOVO HOLDINGS, INC. 0001497253 --03-31 Accelerated Filer 106123048

54974000

62751000

772000

647000

461000

550000

1661000

1144000

57868000

65092000

3528000

3840000

127000

189000

121000

61712000

69180000

558000

1171000

2111000

4101000

165000

157000

854000

582000

3688000

6011000

48000

58000

707000

749000

4443000

6818000

106000

104000

266593000

261586000

-209419000

-199317000

-11000

57269000

62362000

61712000

69180000

0.001

150000000

105724320

104551466

105724320

104551466

944000

674000

46000 213000

4000

990000

891000

301000

168000

5033000

4444000

5856000

5056000

11190000

9668000

-10200000

-8777000

-5000

98000

37000

98000

32000

22000

-10102000

-8767000

-11000

-10113000

-8767000

-0.10

-0.09

104689391

92391964

326000

251000

5000

2052000

1429000

125000

-156000

-89000

178000

518000

41000

-613000

-306000

-1990000

-735000

-34000 -36000

262000

-319000

-10653000

-8541000

11000

12000

70000

-81000

-12000

2957000 0

2957000

-7777000

-8553000

62091000

53538000

22000

<div> Note 2. Stockholders’ Equity Stock-based compensation expense and valuation information Stock-based compensation expense for all stock awards consists of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">331</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">408</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,052</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,429</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The total unrecognized compensation cost related to unvested stock option grants as of June 30, 2017 was approximately $11,430,000 and the weighted average period over which these grants are expected to vest is 2.53 years. The total unrecognized compensation cost related to unvested restricted stock units as of June 30, 2017 was approximately $7,814,000, which will be recognized over a weighted average period of 3.40 years. As of June 30, 2017, there was no unrecognized stock-based compensation expense for restricted stock awards. The total unrecognized stock-based compensation cost related to unvested ESPP shares as of June 30, 2017 was approximately $21,500, which will be recognized over a period of two months. The Company calculates the grant date fair value of all stock-based awards in determining the stock-based compensation expense. Stock-based awards include (i) stock options, (ii) restricted stock awards, (iii) restricted stock units, and (iv) rights to purchase stock under the 2016 Employee Stock Purchase Plan (“ESPP”). The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.27</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.30</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.62</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average grant <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   date fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.03</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Due to the Company’s limited historical data as an early-stage commercial business, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. Certain options granted to consultants are subject to variable accounting treatment and are required to be revalued until vested. The fair value of each restricted stock award is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant. The fair value of each restricted stock unit is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant. The Company uses the Black-Scholes valuation model to calculate the fair value of shares issued pursuant to the Company’s ESPP. Stock-based compensation expense is recognized over the purchase period using the straight-line method. The fair value of ESPP shares was estimated at the purchase period commencement date using the following weighted average assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.14%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.14%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.70</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average grant date fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.04</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Due to the Company’s limited historical data as an early-stage commercial business, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on U.S. Treasury rates. The expected life is the 6-month purchase period.   Preferred stock The Company is authorized to issue 25,000,000 shares of preferred stock. There are no shares of preferred stock currently outstanding, and the Company has no current plans to issue shares of preferred stock.   Common stock In May 2008, the Board of Directors of the Company approved the 2008 Equity Incentive Plan (the “2008 Plan”). The 2008 Plan authorized the issuance of up to 1,521,584 common shares for awards of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock award units, and stock appreciation rights. The 2008 Plan terminates on July 1, 2018. No shares have been issued under the 2008 Plan since 2011, and the Company does not intend to issue any additional shares from the 2008 Plan in the future. In January 2012, the Board of Directors of the Company approved the 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan authorized the issuance of up to 6,553,986 shares of common stock for awards of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance units, performance shares, and other stock or cash awards. The Board of Directors and stockholders of the Company approved an amendment to the 2012 Plan in August 2013 to increase the number of shares of common stock that may be issued under the 2012 Plan by 5,000,000 shares. In addition, the Board of Directors and stockholders of the Company approved an amendment to the 2012 Plan in August 2015 to further increase the number of shares of common stock that may be issued under the 2012 Plan by 6,000,000 shares, bringing the aggregate shares issuable under the 2012 Plan to 17,553,986. The 2012 Plan as amended and restated became effective on August 20, 2015 and terminates ten years after such date. As of June 30, 2017, 1,978,029 shares remain available for issuance under the 2012 Plan. On April 24, 2017 the Company filed a Registration Statement on Form S-8 with the SEC authorizing the issuance of 2,297,034 shares of the Company’s common stock, pursuant to the terms of an Inducement Award Stock Option Agreement and an Inducement Award Performance-Based Restricted Stock Unit Agreement (collectively, the “Inducement Award Agreements”). The Company filed a shelf registration statement on Form S-3 (File No. 333-189995), or the 2013 Shelf, with the SEC on July 17, 2013 authorizing the offer and sale in one or more offerings of up to $100,000,000 in aggregate of common stock, preferred stock, debt securities, or warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities. The 2013 Shelf was declared effective by the SEC on July 26, 2013 and subsequently expired in 2016. A shelf registration statement on Form S-3 (File No. 333-202382), or the 2015 shelf, was filed with the SEC on February 27, 2015 authorizing the offer and sale in one or more offerings of up to $190,000,000 in aggregate of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities. The 2015 shelf was declared effective by the SEC on March 17, 2015. In December 2014, the Company entered into an equity offering sales agreement, or the 2014 Sales Agreement, with an investment banking firm. Under the terms of the distribution agreement, the Company could offer and sell up to $30,000,000 of its shares of common stock, from time to time, through the investment bank in at-the-market offerings, as defined by the SEC, and pursuant to the 2013 Shelf. On July 20, 2016, the Company filed a prospectus supplement to move the remaining $26.6 million of common stock that previously could have been sold pursuant to the 2014 Sales Agreement under the 2013 Shelf to the 2015 Shelf, which does not expire until March 17, 2018. On that same date, the Company filed a post-effective amendment to the 2013 Shelf de-registering all remaining securities that could have been offered by the Company pursuant to the 2013 Shelf.  During the three months ended June 30, 2017 and 2016, the Company issued 1,139,489 and no shares of common stock, respectively, for proceeds of $3.0 million and $0, respectively, in at-the-market offerings under the 2014 Sales Agreement. As of June 30, 2017, the Company has sold an aggregate of 3,136,670 shares of common stock in at-the-market offerings under the 2014 Sales Agreement, with net proceeds of approximately $13.7 million. Based on sales through June 30, 2017, the Company can sell an additional $18.8 million of shares pursuant to the 2014 Sales Agreement under the 2015 Shelf. The Company intends to use the net proceeds raised through any at-the-market sales for general corporate purposes, including research and development, the commercialization of the Company’s products, general administrative expenses, and working capital and capital expenditures. On June 23, 2015, the Company closed the public offering of 10,838,750 shares of its common stock   (the “2015 Offering”), which included the full exercise of the underwriters’ over-allotment. The 2015 Offering was effected pursuant to an Underwriting Agreement (the “2015 Underwriting Agreement”), dated June 18, 2015, with Jefferies LLC and Piper Jaffray & Co. (the “Representatives”), acting as representatives of the underwriters named in the 2015 Underwriting Agreement.  The price to the public in the 2015 Offering was $4.25 per share, and the Underwriters agreed to purchase the shares from the Company pursuant to the 2015 Underwriting Agreement at a price of $3.995 per share.    The net proceeds to the Company from the 2015 Offering were approximately $43.1 million, after deducting underwriting discounts and commissions and expenses payable by the Company. The 2015 Offering was made pursuant to the 2015 Shelf. On October 25, 2016, the Company closed the public offering of 10,065,000 shares (the “2016 Offering”) of its common stock, which included partial exercise of the underwriters’ over-allotment. The 2016 Offering was effected pursuant to an Underwriting Agreement (the “2016 Underwriting Agreement”), dated October 20, 2016, with Jefferies LLC (the “Representative”), acting as representative of the underwriters named in the 2016 Underwriting Agreement. The price to the public in the 2016 Offering was $2.75 per share, and the underwriters purchased the shares from the Company pursuant to the 2016 Underwriting Agreement at a price of $2.585 per share. The net proceeds to the Company from the 2016 Offering were approximately $25.7 million after deducting underwriting discounts and commissions and expenses payable by the Company. The 2016 Offering was made pursuant to the 2015 Shelf. During the three months ended June 30, 2017 and 2016, the Company issued no shares of common stock upon the exercise of warrants. During the three months ended June 30, 2017 and 2016, the Company issued no shares of common stock upon the exercise of stock options. Restricted stock awards During the three months ended June 30, 2017 and 2016, there were 0 and 2,259 shares of restricted stock, respectively, cancelled related to shares of common stock returned to the Company, at the option of the holders, to cover the tax liability related to the vesting of 0 and 6,250 restricted stock awards, respectively. Upon the return of the common stock, an equal number of stock options with immediate vesting were granted to the individuals at the vesting date market value strike price.   Restricted stock units During the three months ended June 30, 2017, the Company issued restricted stock units for an aggregate of 1,862,078 shares of common stock to its employees and directors. These shares of common will be issued upon vesting of the restricted stock units. Vesting generally occurs (i) on the one-year anniversary of the grant date, (ii) quarterly over a three-year period, (iii) quarterly over a four-year period, (iv) over a four-year period, with 25% vesting on the one-year anniversary of the vesting commencement date and the remainder vesting ratably on a quarterly basis over the next twelve quarters, or (v) over a three-year period with 50% vesting on the two-year anniversary of the vesting commencement date and 50% vesting on the three-year anniversary of the vesting commencement date. A summary of the Company’s restricted stock unit activity from March 31, 2017 through June 30, 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at March 31, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,178,114</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.57</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,862,078</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.66</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,221</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.85</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled / forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80,857</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.21</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at June 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,923,114</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.00</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> On April 24, 2017, in connection with the appointment of a new CEO, the Company allocated 208,822 Performance-Based Restricted Stock Units outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of NASDAQ Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. The Board of Directors has not formally approved the vesting criteria for the Performance-Based Restricted Stock Units, therefore these are not considered granted for accounting purposes and no expense has been recognized for the three months ended June 30, 2017. Stock options Under the 2012 Plan, 18,600 and 416,640 stock options were issued during the three months ended June 30, 2017 and 2016, respectively, at various exercise prices based on the closing market price of the Company’s common stock on the date of the grant. The stock options generally vest (i) on the one-year anniversary of the grant date, (ii) quarterly over a three-year period, or (iii) over a four-year period with a quarter vesting on either the one year anniversary of employment or the one year anniversary of the vesting commencement date, and the remainder vesting ratably over the remaining 36 month terms. Stock options can also vest immediately at the grant date or vest after one full year. On April 24, 2017, in connection with the appointment of a new CEO, the Company granted 2,088,212 stock options outside of the 2012 Plan. The Company intends for these to be “inducement grants” within the meaning of NASDAQ Marketplace Rule 5635(c)(4). While granted outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. These stock options vest over a four-year period with a quarter vesting on either the one year anniversary of employment or the one year anniversary of the vesting commencement date. A summary of the Company’s stock option activity for the three months ended June 30, 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March 31, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,956,201</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.63</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,876,437</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,106,812</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.73</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options canceled / forfeited</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(160,464</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.50</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,902,549</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.32</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,210,430</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and Exercisable at June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,420,483</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.69</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,017,444</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The weighted-average remaining contractual term of options exercisable and outstanding at June 30, 2017 was approximately 5.61 years. Employee Stock Purchase Plan In June 2016, our Board of Directors adopted, and in August 2016 stockholders subsequently approved, the 2016 Employee Stock Purchase Plan (“ESPP”). We reserved 1,500,000 shares of common stock for issuance thereunder. The ESPP permits employees after five months of service to purchase common stock through payroll deductions, limited to 15 percent of each employee’s compensation up to $25,000 or 10,000 shares per employee per year. Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period. The initial offering period commenced in September 2016. At June 30, 2017, there were 1,447,443 shares available for purchase under the ESPP. Warrants During the three months ended June 30, 2017 and June 30, 2016, there were no warrant exercises.     The following table summarizes warrant activity for the three months ended June 30, 2017:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,370</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.16</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,370</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.16</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The warrants outstanding at June 30, 2017 are exercisable at prices between $2.28 and $7.62 per share, and have a weighted average remaining term of approximately 1.61 years. Common stock reserved for future issuance Common stock reserved for future issuance consisted of the following at June 30, 2017:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,370</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding under the 2008 Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">622,192</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding and reserved under the 2012 Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,170,174</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved under the 2016 Employee Stock Purchase Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,447,443</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding under the 2012 Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,923,114</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding and reserved under the Inducement Awards</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,088,212</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding under the Inducement Awards</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,822</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total at June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,681,327</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Note 3. Commitments and Contingencies Operating leases The Company leases laboratory and office space in San Diego, California under three non-cancelable leases as described below. Since July 2012, the Company has leased its main facilities at 6275 Nancy Ridge Drive, San Diego, California 92121. The lease, as amended in 2013, 2015 and 2016, consists of approximately 45,580 rentable square feet containing laboratory, clean room and office space. Monthly rental payments are currently approximately $120,000 per month with 3% annual escalators. The lease term for 14,685 of the total rentable square footage expires on December 15, 2018, with the remainder of the rentable square footage expiring on September 1, 2021 with the Company having an option to terminate this lease on or after September 1, 2019.     On January 9, 2015, the Company entered into an agreement to lease a second facility consisting of 5,803 rentable square feet of office and lab space located at 6310 Nancy Ridge Drive, San Diego, California 92121. The term of the lease is 36 months, beginning on February 1, 2015 and ending on January 31, 2018, with monthly rental payments of approximately $12,000 commencing on April 1, 2015. In addition, there are annual rent escalations of 3% on each 12-month anniversary of the lease commencement date. In addition to these two leases, the Company leased a third facility from February 1, 2016 through January 31, 2017, consisting of 12,088 rentable square feet of office space located at 6166 Nancy Ridge Drive, San Diego, California 92121 with a monthly rent of $15,000. The Company records rent expense on a straight-line basis over the life of the leases and records the excess of expense over the amounts paid as deferred rent. In addition, one of the leases provides for certain improvements made for the Company’s benefit to be funded by the landlord. Such costs, totaling approximately $518,000 to date, have been capitalized as fixed assets and included in deferred rent. Rent expense was approximately $366,000 and $303,000 for the three months ended June 30, 2017 and 2016, respectively. Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2017, are as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,196</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,465</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,073</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,104</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2022</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,306</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Legal Matters In addition to commitments and obligations in the ordinary course of business, the Company may be subject, from time to time, to various claims and pending and potential legal actions arising out of the normal conduct of its business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against it may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability. The Company regularly reviews contingencies to determine the adequacy of its accruals and related disclosures. During the period presented, the Company has not recorded any accrual for loss contingencies associated with such claims or legal proceedings; determined that an unfavorable outcome is probable or reasonably possible; or determined that the amount or range of any possible loss is reasonably estimable. However, the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against the Company in a reporting period, the Company’s consolidated financial statements for that reporting period could be materially adversely affected.</div>

<div> Note 4. Concentrations Credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions primarily located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company has not experienced losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents. The Company is also potentially subject to concentrations of credit risk in its revenues and accounts receivable. Because it is in the early commercial stage, the Company’s revenues to date have been derived from a relatively small number of customers and collaborators. However, the Company has not historically experienced any accounts receivable write-downs and management does not believe significant credit risk exists as of June 30, 2017. </div>

<div> Note 5. Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard was originally effective for public companies for annual reporting periods beginning after December 15, 2016, with no early application permitted. In August 2015, the FASB issued ASU No. 2015-14 that defers by one year the effective date for all entities, with application permitted as of the original effective date. The updated standard becomes effective for us on April 1, 2018, with early adoption permitted as of April 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that this update will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of this updated standard on our ongoing financial reporting. We do not have plans to adopt this standard prior to the effective date. In February 2016, the FASB issued ASU 2016-02, Leases, which requires an entity to recognize lease assets and lease liabilities on the balance sheet for leases with terms of more than 12 months and to disclose key information about leasing arrangements. This new guidance is effective for us on April 1, 2019, with early adoption permitted in any interim or annual period. The Company is currently evaluating the impact that this guidance will have on its financial statements and related disclosures. In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718), which requires an entity recognize excess tax benefits and deficiencies as income tax expense or benefit, the cash flows of which should be included as operating activity in the statement of cash flows. An entity is allowed to either continue accruing compensation cost based on expected forfeitures or to begin recognizing expense as forfeitures occur. In addition, an entity may withhold the maximum statutory tax, increasing the allowable cash settlement portion of awards. The cash paid by an employer when directly withholding shares for tax purposes should be included in the financing activity section of the statement of cash flows. This new guidance became effective for us on April 1, 2017. The requirements of ASU 2016-09 did not have a significant impact on our consolidated financial statements.</div>

<div> Note 6. Subsequent Events During July 2017, the Company issued 398,728 shares of its common stock pursuant to its at-the-market (“ATM”) facility for net proceeds exceeding $1.0 million.     </div>

<div> Nature of operations and basis of presentation References in these notes to the unaudited condensed consolidated financial statements to “Organovo Holdings, Inc.,” “Organovo Holdings,” “we,” “us,” “our,” “the Company” and “our Company” refer to Organovo Holdings, Inc. and its consolidated subsidiaries. Our consolidated financial statements include the accounts of the Company as well as its wholly-owned subsidiaries, with all material intercompany accounts and transactions eliminated in consolidation. In December 2014, we established a wholly-owned subsidiary, Samsara Sciences, Inc., to focus on the acquisition of qualified cells in support of our commercial and research endeavors. In September 2015, we established another wholly-owned subsidiary in the United Kingdom, Organovo U.K., Ltd., for the primary purpose of establishing a sales presence in Europe. Since its inception, the Company has devoted its efforts primarily to developing and commercializing a platform technology and functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company has also focused efforts on raising capital and building infrastructure. In November 2014, the Company announced the commercial release of its first product, the ExVive™ Human Liver Tissue for use in toxicology and other preclinical drug testing. In September 2016, the Company announced that it had begun commercial contracting for services relating to its second product, the ExVive™ Human Kidney tissue. The Company’s activities are subject to significant risks and uncertainties including failing to successfully develop products and services based on its technology and to achieve the market acceptance necessary to generate sufficient revenues to support its operations and to achieve and sustain profitability. The accompanying interim condensed consolidated financial statements have been prepared by the Company, without audit, in accordance with the instructions to Form 10-Q and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of its financial position, results of operations, stockholders’ equity and cash flows in accordance with generally accepted accounting principles (“GAAP”). The balance sheet at March 31, 2017 is derived from the Company’s audited balance sheet at that date. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These financial statements should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2017, filed with the Securities and Exchange Commission (the “SEC”) on June 7, 2017. Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2018. </div> <div> Liquidity As of June 30, 2017, the Company had cash and cash equivalents of approximately $55.0 million and an accumulated deficit of approximately $209.4 million. The Company also had negative cash flows from operations of approximately $10.7 million during the three months ended June 30, 2017. Through June 30, 2017, the Company has financed its operations primarily through the sale of convertible notes, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative research agreements, grants, and licenses. During the quarter ended June 30, 2017, the Company issued 1,139,489 shares of its common stock through its ATM facility and received net proceeds of approximately $3.0 million. On October 25, 2016, the Company closed the issuance and sale of 10,065,000 shares of its common stock in an underwritten public offering. The Company received net proceeds of approximately $25.7 million in the offering, after deducting underwriting discounts and commissions and the Company’s expenses. Based on its current operating plan and available cash resources, the Company has sufficient resources to fund its business for at least the next twelve months from the financial statement issuance date. The Company will need additional capital to further fund the development and commercialization of its human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or diseased tissues and organs. The Company intends to cover its future operating expenses through cash on hand, through revenue derived from research service agreements, product sales, collaborative research agreements, grants and royalty payments, and through the issuance of additional equity or debt securities. Depending on market conditions, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. Having insufficient funds may require us to delay, scale back, or eliminate some or all of our development programs or relinquish rights to our technology on less favorable terms than we would otherwise choose. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.</div>

<div>   Revenue recognition The Company’s revenues are derived from research service agreements, product sales, collaborative research agreements, grants and license- payments from the National Institutes of Health (“NIH”), U.S. Treasury Department, academic institutions, and private not-for-profit organizations. The Company recognizes revenue when the following criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) services have been rendered or product has been delivered; (iii) price to the customer is fixed and determinable; and (iv) collection of the underlying receivable is reasonably assured. Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of June 30, 2017 and March 31, 2017, the Company had approximately $903,000 and $640,000, respectively, in deferred revenue related to its grants and royalty payments, collaborative research programs and research service agreements. </div>

<div> Revenue from research service agreements For research service agreements that contain only a single or primary deliverable, the Company defers any up-front fees collected from customers, and recognizes revenue for the delivered element only when it determines there are no uncertainties regarding customer acceptance. For agreements that contain multiple deliverables, the Company follows ASC 605-25 as described above. </div> <div> Research and development revenue under collaborative agreements The Company’s collaboration revenue consists of license and collaboration agreements that contain multiple elements, which may include non-refundable up-front fees, payments for reimbursement of third-party research costs, payments for ongoing research, payments associated with achieving specific development milestones and royalties based on specified percentages of net product sales, if any. The Company considers a variety of factors in determining the appropriate method of revenue recognition under these arrangements, such as whether the elements are separable, whether there are determinable fair values and whether there is a unique earnings process associated with each element of a contract. The Company recognizes revenue from research funding under collaboration agreements when earned on a “proportional performance” basis as research services are provided or substantive milestones are achieved. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to us for the milestone (i) is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance, (ii) relates solely to our past performance and (iii) is reasonable relative to all of the other deliverables and payments within the arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the risks that must be overcome to achieve the milestone, the level of effort and investment required to achieve the milestone and whether any portion of the milestone consideration is related to future performance or deliverables. The Company initially defers revenue for any amounts billed or payments received in advance of the services being performed, and recognizes revenue pursuant to the related pattern of performance, using the appropriate method of revenue recognition based on its analysis of the related contractual element(s). In November 2014, the Company entered into a collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter at the university for the purpose of developing bioprinted tissues for surgical transplantation research. The Company has recorded $0 and $12,500 for the three months ended June 30, 2017 and 2016, respectively, in revenue related to this collaboration in recognition of the proportional performance achieved. In April 2015, the Company entered into a research collaboration agreement with a third party to develop custom tissue models for fixed fees. Based on the proportional performance achieved under this agreement, no collaboration revenue was recorded for the three months ended June 30, 2017 or 2016. Also in April 2015, the Company entered into a multi-year research agreement with a third party to develop multiple custom tissue models for use in drug development. Approximately $0 and $200,000 were recorded as revenue in recognition of the proportional performance achieved under this agreement during the three months ended June 30, 2017 and 2016, respectively. In June 2016, the Company announced it had entered into another collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter at the university for the purpose of developing bioprinted tissues for skeletal disease research. The Company received an up-front payment in June 2016, which was initially been recorded as deferred revenue. Revenue of $17,000 and $0 has been recorded under this agreement during the three months ended June 30, 2017 and 2016, respectively. In December 2016, the Company signed another collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter at the university for the purpose of developing an architecturally correct kidney for potential therapeutic applications. The Company received an up-front payment in January and March of 2017, which has been recorded as deferred revenue. Revenue of $10,000 has been recorded under this agreement for the three months ended June 30, 2017.</div>

<div> Stock-based compensation expense for all stock awards consists of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">331</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">408</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,052</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,429</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The fair value of stock options was estimated at the grant date using the following weighted average assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.9%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.27</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.30</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.62</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average grant <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   date fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.03</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The fair value of ESPP shares was estimated at the purchase period commencement date using the following weighted average assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.14%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.14%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.70</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average grant date fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.04</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> A summary of the Company’s stock option activity for the three months ended June 30, 2017 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March 31, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,956,201</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.63</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,876,437</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,106,812</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.73</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options canceled / forfeited</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(160,464</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.50</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at June 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,902,549</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.32</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,210,430</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and Exercisable at June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,420,483</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.69</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,017,444</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Common stock reserved for future issuance consisted of the following at June 30, 2017:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,370</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding under the 2008 Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">622,192</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding and reserved under the 2012 Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,170,174</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved under the 2016 Employee Stock Purchase Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,447,443</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding under the 2012 Plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,923,114</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options outstanding and reserved under the Inducement Awards</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,088,212</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding under the Inducement Awards</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,822</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total at June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,681,327</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2017, are as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,196</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,465</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,073</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,104</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fiscal year ended March 31, 2022</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,306</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

1139489

3000000

10065000

25700000

2017-03-31

903000

640000

0 12500 0 0 0 200000 17000 0 10000 251700

4000

16000000

11600000

331000

408000

1721000

1021000

2052000

1429000

11430000

P2Y6M11D

7814000

P3Y4M24D

21500

P2M

0.00

0.7427

0.7130

0.0162

0.0120

P6Y

1.79

2.03

0.00

0.7470

0.0079

P6M

1.04

25000000

1521584

2018-07-01

6553986

5000000

6000000

17553986

1978029

P10Y

2297034

100000000 2016 190000000

30000000

26600000

2018-03-17

1139489

3000000

3136670

13700000

18800000

10838750

4.25

3.995

43100000

2.75

2.585

25700000

0 0

0 2259

6250

0 2259

1862078

Vesting generally occurs (i) on the one-year anniversary of the grant date, (ii) quarterly over a three-year period, (iii) quarterly over a four-year period, (iv) over a four-year period, with 25% vesting on the one-year anniversary of the vesting commencement date and the remainder vesting ratably on a quarterly basis over the next twelve quarters, or (v) over a three-year period with 50% vesting on the two-year anniversary of the vesting commencement date and 50% vesting on the three-year anniversary of the vesting commencement date.

P4Y

0.25

P36M 0.50 0.50

1178114

36221

80857

2923114

3.57

2.66

3.85

3.21

3.00

208822

18600

416640

stock options generally vest (i) on the one-year anniversary of the grant date, (ii) quarterly over a three-year period, or (iii) over a four-year period with a quarter vesting on either the one year anniversary of employment or the one year anniversary of the vesting commencement date

P36M

2088212

P4Y

These stock options vest over a four-year period with a quarter vesting on either the one year anniversary of employment or the one year anniversary of the vesting commencement date.

10956201

2106812

160464

12902549

7420483

4.63

2.73

4.50

4.32

4.69

4876437

3210430

3017444

P5Y7M10D

1500000

0.15

25000

10000

0.85

P6M 2016-09

Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period.

1447443

0 0

221370

7.16

2.28

7.62

P1Y7M10D

221370

622192

12170174

1447443

2923114

2088212

208822

19681327

3 120000

0.03

45580 14685

2021-09-01

2018-12-15

option to terminate this lease on or after September 1, 2019 5803

P36M

2015-02-01 2018-01-31 12000

0.03

12088 2016-02-01 2017-01-31 15000 518000

366000

303000

1196000

1465000

1073000

1104000

468000

5306000

398728

1000000 EX-101.SCH 6 onvo-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100050 - Disclosure - Description of Business and Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Concentrations link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Options (Detail) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Stockholders' Equity - Preferred Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Stockholders' Equity - Common Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Stockholders' Equity - Restricted Stock Awards and Restricted Stock Units - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Stockholders' Equity - Summary of Company's Restricted Stock Unit Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Stockholders' Equity - Warrants - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments Required under Operating Leases that have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 onvo-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 onvo-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 onvo-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and entity information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current Assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable Accounts Receivable Net Current Inventory, net Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Fixed assets, net Property Plant And Equipment Net Restricted cash Restricted Cash And Cash Equivalents Noncurrent Other assets, net Other Assets Noncurrent Total assets Assets Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity [Abstract] Current Liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Deferred rent Deferred Rent Credit Current Deferred revenue Deferred Revenue Current Total current liabilities Liabilities Current Deferred revenue, net of current portion Deferred Revenue Noncurrent Deferred rent, net of current portion Deferred Rent Credit Noncurrent Total liabilities Liabilities Commitments and Contingencies (Note 4) Commitments And Contingencies Stockholders’ Equity Stockholders Equity [Abstract] Common stock, $0.001 par value; 150,000,000 shares authorized, 105,724,320 and 104,551,466 shares issued and outstanding at June 30, 2017 and March 31, 2017, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income Loss Net Of Tax Total stockholders’ equity Stockholders Equity Total Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Revenue from research collaborations and licenses. Income Statement [Abstract] Revenues Revenues [Abstract] Products and services Sales Revenue Net Collaborations and licenses Revenue From Research Collaborations And Licenses Grants Revenue From Grants Total Revenues Revenues Cost of revenues Cost Of Revenue Research and development expenses Research And Development Expense Selling, general, and administrative expenses Selling General And Administrative Expense Total costs and expenses Costs And Expenses Loss from Operations Operating Income Loss Other Income (Expense) Nonoperating Income Expense [Abstract] Change in fair value of warrant liabilities Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net Interest income Investment Income Interest Total Other Income (Expense) Nonoperating Income Expense Income Tax Expense Income Tax Expense Benefit Net Loss Net Income Loss Currency Translation Adjustment Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Comprehensive Loss Comprehensive Income Net Of Tax Net loss per common share—basic and diluted Earnings Per Share Basic And Diluted Weighted average shares used in computing net loss per common share—basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Increase decrease in deferred rent. Proceeds from issuance of common stock and warrants. Statement Of Cash Flows [Abstract] Cash Flows From Operating Activities Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Change in fair value of warrant liabilities Fair Value Adjustment Of Warrants Stock-based compensation Share Based Compensation Increase (decrease) in cash resulting from changes in: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Inventory Increase Decrease In Inventories Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued expenses Increase Decrease In Accrued Liabilities Deferred rent Increase Decrease In Deferred Rent Deferred revenue Increase Decrease In Deferred Revenue Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash Flows From Investing Activities Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchases of fixed assets Payments To Acquire Property Plant And Equipment Purchases of intangible assets Payments To Acquire Intangible Assets Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash Flows From Financing Activities Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Proceeds from issuance of common stock and exercise of warrants, net Proceeds From Issuance Of Common Stock And Warrants Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net Increase (Decrease) in Cash and Cash Equivalents Cash And Cash Equivalents Period Increase Decrease Cash and Cash Equivalents at Beginning of Period Cash and Cash Equivalents at End of Period Supplemental Disclosure of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid Income taxes paid Income Taxes Paid Accounting Policies [Abstract] Description of Business and Summary of Significant Accounting Policies Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Text Block] Equity [Abstract] Stockholders' Equity Shareholders Equity And Share Based Payments [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments Disclosure [Text Block] Risks And Uncertainties [Abstract] Concentrations Concentration Risk Disclosure [Text Block] Accounting Changes And Error Corrections [Abstract] Recent Accounting Pronouncements New Accounting Pronouncements And Changes In Accounting Principles [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Nature of operations and basis of presentation. Nature of Operations and Basis of Presentation Nature Of Operations And Basis Of Presentation Policy [Text Block] Liquidity policy. Liquidity Liquidity Policy [Text Block] Use of estimates Use Of Estimates Fair value measurement Fair Value Measurement Policy Policy [Text Block] Revenue recognition Revenue Recognition Policy [Text Block] Revenue arrangements with multiple deliverables Revenue Recognition Multiple Element Arrangements Revenue recognition single element arrangements. Revenue from research service agreements Revenue Recognition Single Element Arrangements Policy [Text Block] Revenue recognition research and development revenue. Research and development revenue under collaborative agreements Revenue Recognition Research And Development Revenue Policy [Text Block] Product revenue Revenue Recognition Sales Of Goods Revenue recognition grant. Grant revenue Revenue Recognition Grant Policy [Text Block] Cost of revenues Cost Of Sales Policy [Text Block] Net loss per share Earnings Per Share Policy [Text Block] Schedule of Stock-based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Fair Value of Employee Stock Options Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Fair Value of Employee Stock Purchase Plan Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block] Summary of Company's Restricted Stock Unit Activity Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block] Summary of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Warrant Activity Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block] Common stock capital shares reserved for future issuance. Common Stock Reserved for Future Issuance Common Stock Capital Shares Reserved For Future Issuance Table [Text Block] Future Minimum Rental Payments Required under Operating Leases that have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block] Description of business and summary of significant accounting policies. Description of business and summary of significant accounting policies. Description Of Business And Summary Of Significant Accounting Policies [Table] Description Of Business And Summary Of Significant Accounting Policies [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] At-the-market facility. At-The-Market Facility [Member] At The Market Facility [Member] Over Allotment Option [Member] Over Allotment Option [Member] Secondary offering member. Secondary Offering [Member] Secondary Offering [Member] Other Commitments Other Commitments [Axis] Other Commitments Other Commitments [Domain] Two thousand sixteen underwriting agreement. 2016 Underwriting Agreement [Member] Two Thousand Sixteen Underwriting Agreement [Member] Category of Item Purchased Long Term Purchase Commitment By Category Of Item Purchased [Axis] Long-term Purchase Commitment, Category of Item Purchased Long Term Purchase Commitment Category Of Item Purchased [Domain] Research and Development Services [Member] Research And Development Arrangement [Member] Research and development arrangement six. Research and Development Services Six [Member] Research And Development Arrangement Six [Member] Research and development arrangement four. Research and Development Services Four [Member] Research And Development Arrangement Four [Member] Research and development arrangement five. Research and Development Services Five [Member] Research And Development Arrangement Five [Member] Research and development arrangement seven. Research and Development Services Seven [Member] Research And Development Arrangement Seven [Member] Research and development arrangement eight. Research and Development Services Eight [Member] Research And Development Arrangement Eight [Member] Range Range [Axis] Range Range [Member] Maximum [Member] Maximum [Member] Principal Transaction Revenue, Description of Reporting Category Principle Transaction Revenue Description Of Reporting Category [Axis] Name of Reporting Category Name Of Reporting Category [Domain] Private. Private, Not-for-Profit Organization [Member] Private [Member] Description Of Business And Summary Of Significant Accounting Policies [Line Items] Description Of Business And Summary Of Significant Accounting Policies [Line Items] Cash flow from operations Issuance of common stock Gross proceeds from sale of common stock shares Proceeds From Issuance Of Common Stock Warrants expiration date Investment Warrants Expiration Date Deferred revenue Revenue from research collaborations. Revenue related to research contract Revenue From Research Collaborations Research grant. Revenue recognized under grants Research Grant Revenue recognized under grants Dilutive effect Dilutive Securities Common stock equivalents excluded from computing diluted net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and development Research And Development Expense [Member] General and administrative General And Administrative Expense [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Total stock-based compensation expense Allocated Share Based Compensation Expense Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Stock options [Member] Employee Stock Option [Member] Restricted stock units (RSUs) [Member] Restricted Stock Units R S U [Member] Restricted stock [Member] Restricted Stock [Member] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Employee Stock Purchase Plan. Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Total unrecognized compensation cost related to unvested stock option grants Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Total unrecognized compensation cost related, weighted average period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Unrecognized stock-based compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options Dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Expected life of options Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Weighted average grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Employee Stock Purchase Plan Two Thousand Sixteen [Member] 2016 Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan Two Thousand Sixteen [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Expected term Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares outstanding Preferred Stock Shares Outstanding Equity incentive plan. Equity Incentive Plan 2008 [Member] Equity Incentive Plan Two Thousand Eight [Member] Equity incentive plan two thousand twelve. Equity Incentive Plan 2012 [Member] Equity Incentive Plan Two Thousand Twelve [Member] Inducement award agreements. Inducement Award Agreements [Member] Inducement Award Agreements [Member] IPO [Member] I P O [Member] Equity distribution agreement. Equity Distribution Agreement [Member] Equity Distribution Agreement [Member] EX-101.PRE 10 onvo-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Jul. 31, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Trading Symbol	ONVO
Entity Registrant Name	ORGANOVO HOLDINGS, INC.
Entity Central Index Key	0001497253
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		106,123,048

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Mar. 31, 2017
Current Assets
Cash and cash equivalents	$ 54,974	$ 62,751
Accounts receivable	772	647
Inventory, net	461	550
Prepaid expenses and other current assets	1,661	1,144
Total current assets	57,868	65,092
Fixed assets, net	3,528	3,840
Restricted cash	127	127
Other assets, net	189	121
Total assets	61,712	69,180
Current Liabilities
Accounts payable	558	1,171
Accrued expenses	2,111	4,101
Deferred rent	165	157
Deferred revenue	854	582
Total current liabilities	3,688	6,011
Deferred revenue, net of current portion	48	58
Deferred rent, net of current portion	707	749
Total liabilities	4,443	6,818
Commitments and Contingencies (Note 4)	0	0
Stockholders’ Equity
Common stock, $0.001 par value; 150,000,000 shares authorized, 105,724,320 and 104,551,466 shares issued and outstanding at June 30, 2017 and March 31, 2017, respectively	106	104
Additional paid-in capital	266,593	261,586
Accumulated deficit	(209,419)	(199,317)
Accumulated other comprehensive income (loss)	(11)	(11)
Total stockholders’ equity	57,269	62,362
Total Liabilities and Stockholders’ Equity	$ 61,712	$ 69,180

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Mar. 31, 2016
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	105,724,320	104,551,466
Common stock, shares outstanding	105,724,320	104,551,466

XML 14 R4.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Revenues
Products and services	$ 944	$ 674
Collaborations and licenses	46	213
Grants	0	4
Total Revenues	990	891
Cost of revenues	301	168
Research and development expenses	5,033	4,444
Selling, general, and administrative expenses	5,856	5,056
Total costs and expenses	11,190	9,668
Loss from Operations	(10,200)	(8,777)
Other Income (Expense)
Change in fair value of warrant liabilities	0	(5)
Interest income	98	37
Total Other Income (Expense)	98	32
Income Tax Expense	0	(22)
Net Loss	(10,102)	(8,767)
Currency Translation Adjustment	(11)	0
Comprehensive Loss	$ (10,113)	$ (8,767)
Net loss per common share—basic and diluted	$ (0.10)	$ (0.09)
Weighted average shares used in computing net loss per common share—basic and diluted	104,689,391	92,391,964

XML 15 R5.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash Flows From Operating Activities
Net loss	$ (10,102)	$ (8,767)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	326	251
Change in fair value of warrant liabilities	0	5
Stock-based compensation	2,052	1,429
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(125)	156
Inventory	89	(178)
Prepaid expenses and other assets	(518)	(41)
Accounts payable	(613)	(306)
Accrued expenses	(1,990)	(735)
Deferred rent	(34)	(36)
Deferred revenue	262	(319)
Net cash used in operating activities	(10,653)	(8,541)
Cash Flows From Investing Activities
Purchases of fixed assets	(11)	(12)
Purchases of intangible assets	(70)	0
Net cash used in investing activities	(81)	(12)
Cash Flows From Financing Activities
Proceeds from issuance of common stock and exercise of warrants, net	2,957	0
Net cash provided by financing activities	2,957	0
Net Increase (Decrease) in Cash and Cash Equivalents	(7,777)	(8,553)
Cash and Cash Equivalents at Beginning of Period	62,751	62,091
Cash and Cash Equivalents at End of Period	54,974	53,538
Supplemental Disclosure of Cash Flow Information:
Interest paid	0	0
Income taxes paid	$ 0	$ 22

XML 16 R6.htm IDEA: XBRL DOCUMENT

Description of Business and Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Description of Business and Summary of Significant Accounting Policies	Note 1. Description of Business and Summary of Significant Accounting Policies Nature of operations and basis of presentation References in these notes to the unaudited condensed consolidated financial statements to “Organovo Holdings, Inc.,” “Organovo Holdings,” “we,” “us,” “our,” “the Company” and “our Company” refer to Organovo Holdings, Inc. and its consolidated subsidiaries. Our consolidated financial statements include the accounts of the Company as well as its wholly-owned subsidiaries, with all material intercompany accounts and transactions eliminated in consolidation. In December 2014, we established a wholly-owned subsidiary, Samsara Sciences, Inc., to focus on the acquisition of qualified cells in support of our commercial and research endeavors. In September 2015, we established another wholly-owned subsidiary in the United Kingdom, Organovo U.K., Ltd., for the primary purpose of establishing a sales presence in Europe. Since its inception, the Company has devoted its efforts primarily to developing and commercializing a platform technology and functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company has also focused efforts on raising capital and building infrastructure. In November 2014, the Company announced the commercial release of its first product, the ExVive™ Human Liver Tissue for use in toxicology and other preclinical drug testing. In September 2016, the Company announced that it had begun commercial contracting for services relating to its second product, the ExVive™ Human Kidney tissue. The Company’s activities are subject to significant risks and uncertainties including failing to successfully develop products and services based on its technology and to achieve the market acceptance necessary to generate sufficient revenues to support its operations and to achieve and sustain profitability. The accompanying interim condensed consolidated financial statements have been prepared by the Company, without audit, in accordance with the instructions to Form 10-Q and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of its financial position, results of operations, stockholders’ equity and cash flows in accordance with generally accepted accounting principles (“GAAP”). The balance sheet at March 31, 2017 is derived from the Company’s audited balance sheet at that date. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These financial statements should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2017, filed with the Securities and Exchange Commission (the “SEC”) on June 7, 2017. Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2018. Liquidity As of June 30, 2017, the Company had cash and cash equivalents of approximately $55.0 million and an accumulated deficit of approximately $209.4 million. The Company also had negative cash flows from operations of approximately $10.7 million during the three months ended June 30, 2017. Through June 30, 2017, the Company has financed its operations primarily through the sale of convertible notes, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative research agreements, grants, and licenses. During the quarter ended June 30, 2017, the Company issued 1,139,489 shares of its common stock through its ATM facility and received net proceeds of approximately $3.0 million. On October 25, 2016, the Company closed the issuance and sale of 10,065,000 shares of its common stock in an underwritten public offering. The Company received net proceeds of approximately $25.7 million in the offering, after deducting underwriting discounts and commissions and the Company’s expenses. Based on its current operating plan and available cash resources, the Company has sufficient resources to fund its business for at least the next twelve months from the financial statement issuance date. The Company will need additional capital to further fund the development and commercialization of its human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or diseased tissues and organs. The Company intends to cover its future operating expenses through cash on hand, through revenue derived from research service agreements, product sales, collaborative research agreements, grants and royalty payments, and through the issuance of additional equity or debt securities. Depending on market conditions, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. Having insufficient funds may require us to delay, scale back, or eliminate some or all of our development programs or relinquish rights to our technology on less favorable terms than we would otherwise choose. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Use of estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the condensed consolidated financial statements include those assumed in revenue recognized under the proportional performance model, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets. Fair value measurement The Company had issued warrants, of which some were classified as derivative liabilities as a result of the terms in the warrants that provide for down-round protection in the event of a dilutive issuance. The Company used Level 3 inputs (unobservable inputs that are supported by little or no market activity, and that are significant to the fair value of the assets or liabilities) for its valuation methodology for the warrant derivative liabilities. The estimated fair values were determined using a Monte Carlo option pricing model based on various assumptions. The Company’s derivative liabilities were adjusted to reflect estimated fair value at each period end, with any increase or decrease in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of the derivative liabilities. Various factors are considered in the pricing models the Company used to value the warrants, including the Company’s current stock price, the remaining life of the warrant, the volatility of the Company’s stock price, and the risk-free interest rate. The remaining warrants expired as of March 31, 2017 and were removed from the Balance Sheet. The Company does not have any financial assets or liabilities measured on a fair value basis as of June 30, 2017 or March 31, 2017. Revenue recognition The Company’s revenues are derived from research service agreements, product sales, collaborative research agreements, grants and license- payments from the National Institutes of Health (“NIH”), U.S. Treasury Department, academic institutions, and private not-for-profit organizations. The Company recognizes revenue when the following criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) services have been rendered or product has been delivered; (iii) price to the customer is fixed and determinable; and (iv) collection of the underlying receivable is reasonably assured. Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of June 30, 2017 and March 31, 2017, the Company had approximately $903,000 and $640,000, respectively, in deferred revenue related to its grants and royalty payments, collaborative research programs and research service agreements. Revenue arrangements with multiple deliverables The Company follows ASC 605-25 Revenue Recognition – Multiple-Element Arrangements for revenue arrangements that contain multiple deliverables. Judgment is required to properly identify the accounting units of the multiple deliverable transactions and to determine the manner in which revenue should be allocated among the accounting units. Moreover, judgment is used in interpreting the commercial terms and determining when all criteria of revenue recognition have been met for each deliverable in order for revenue recognition to occur in the appropriate accounting period. For multiple deliverable agreements, consideration is allocated at the inception of the agreement to all deliverables based on their relative selling price. The relative selling price for each deliverable is determined using vendor-specific objective evidence (“VSOE”) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable. While changes in the allocation of the arrangement consideration between the units of accounting will not affect the amount of total revenue recognized for a particular sales arrangement, any material changes in these allocations could impact the timing of revenue recognition, which could affect the Company’s results of operations. The Company periodically receives license fees for non-exclusive research licensing associated with funded research projects. License fees under these arrangements are recognized over the term of the contract or development period as it has been determined that such licenses do not have stand-alone value. Revenue from research service agreements For research service agreements that contain only a single or primary deliverable, the Company defers any up-front fees collected from customers, and recognizes revenue for the delivered element only when it determines there are no uncertainties regarding customer acceptance. For agreements that contain multiple deliverables, the Company follows ASC 605-25 as described above. Research and development revenue under collaborative agreements The Company’s collaboration revenue consists of license and collaboration agreements that contain multiple elements, which may include non-refundable up-front fees, payments for reimbursement of third-party research costs, payments for ongoing research, payments associated with achieving specific development milestones and royalties based on specified percentages of net product sales, if any. The Company considers a variety of factors in determining the appropriate method of revenue recognition under these arrangements, such as whether the elements are separable, whether there are determinable fair values and whether there is a unique earnings process associated with each element of a contract. The Company recognizes revenue from research funding under collaboration agreements when earned on a “proportional performance” basis as research services are provided or substantive milestones are achieved. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to us for the milestone (i) is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance, (ii) relates solely to our past performance and (iii) is reasonable relative to all of the other deliverables and payments within the arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the risks that must be overcome to achieve the milestone, the level of effort and investment required to achieve the milestone and whether any portion of the milestone consideration is related to future performance or deliverables. The Company initially defers revenue for any amounts billed or payments received in advance of the services being performed, and recognizes revenue pursuant to the related pattern of performance, using the appropriate method of revenue recognition based on its analysis of the related contractual element(s). In November 2014, the Company entered into a collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter at the university for the purpose of developing bioprinted tissues for surgical transplantation research. The Company has recorded $0 and $12,500 for the three months ended June 30, 2017 and 2016, respectively, in revenue related to this collaboration in recognition of the proportional performance achieved. In April 2015, the Company entered into a research collaboration agreement with a third party to develop custom tissue models for fixed fees. Based on the proportional performance achieved under this agreement, no collaboration revenue was recorded for the three months ended June 30, 2017 or 2016. Also in April 2015, the Company entered into a multi-year research agreement with a third party to develop multiple custom tissue models for use in drug development. Approximately $0 and $200,000 were recorded as revenue in recognition of the proportional performance achieved under this agreement during the three months ended June 30, 2017 and 2016, respectively. In June 2016, the Company announced it had entered into another collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter at the university for the purpose of developing bioprinted tissues for skeletal disease research. The Company received an up-front payment in June 2016, which was initially been recorded as deferred revenue. Revenue of $17,000 and $0 has been recorded under this agreement during the three months ended June 30, 2017 and 2016, respectively. In December 2016, the Company signed another collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter at the university for the purpose of developing an architecturally correct kidney for potential therapeutic applications. The Company received an up-front payment in January and March of 2017, which has been recorded as deferred revenue. Revenue of $10,000 has been recorded under this agreement for the three months ended June 30, 2017. Product revenue The Company recognizes product revenue at the time of shipment to the customer, provided all other revenue recognition criteria have been met. As our commercial sales increase, we expect to establish a reserve for estimated product returns that will be recorded as a reduction to revenue. This reserve will be maintained to account for future return of products sold in the current period. The reserve will be reviewed quarterly and will be estimated based on an analysis of our historical experience related to product returns. Grant revenue During August 2013, the Company was awarded a research grant by a private, not-for-profit organization for up to $251,700, contingent on go/no-go decisions made by the grantor at the completion of each stage of research as outlined in the grant award. Revenues from the grant are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized when the Company incurs expenses that are related to the grant. Revenue recognized under this grant was approximately $0 and $4,000 for the three months ended June 30, 2017 and 2016, respectively. The Company has completed its obligations under this agreement as of June 30, 2017. Cost of revenues The Company reported $0.3 million and $0.2 million in cost of revenues for the three months ended June 30, 2017 and 2016, respectively. This captures our costs related to manufacturing and delivering our product and service revenue. Net loss per share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three months ended June 30, 2017 and 2016, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Common stock equivalents excluded from computing diluted net loss per share were approximately 16.0 million for the three months ended June 30, 2017, and 11.6 million for the three months ended June 30, 2016.

XML 17 R7.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Jun. 30, 2017

Equity [Abstract]

Stockholders' Equity

Note 2. Stockholders’ Equity

Stock-based compensation expense and valuation information

Stock-based compensation expense for all stock awards consists of the following (in thousands):

	Three Months Ended		Three Months Ended
	June 30, 2017		June 30, 2016
Research and development	$	331	$	408
General and administrative	$	1,721	$	1,021
Total	$	2,052	$	1,429

As of June 30, 2017, there was no unrecognized stock-based compensation expense for restricted stock awards.

The total unrecognized stock-based compensation cost related to unvested ESPP shares as of June 30, 2017 was approximately $21,500, which will be recognized over a period of two months.

	Three Months Ended			Three Months Ended
	June 30, 2017			June 30, 2016
Dividend yield		—			—
Volatility		74.27	%		71.30	%
Risk-free interest rate		1.62	%		1.20	%
Expected life of options	6.00 years			6.00 years
Weighted average grant date fair value	$	1.79		$	2.03

	Three Months Ended
	June 30, 2017
Dividend yield		—
Volatility		74.70	%
Risk-free interest rate		0.79	%
Expected term	6 months
Weighted average grant date fair value	$	1.04

Preferred stock

Common stock

During the three months ended June 30, 2017 and 2016, the Company issued no shares of common stock upon the exercise of warrants.

During the three months ended June 30, 2017 and 2016, the Company issued no shares of common stock upon the exercise of stock options.

Restricted stock awards

Restricted stock units

A summary of the Company’s restricted stock unit activity from March 31, 2017 through June 30, 2017 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2017		1,178,114		$	3.57
Granted		1,862,078		$	2.66
Vested		(36,221	)	$	3.85
Canceled / forfeited		(80,857	)	$	3.21
Unvested at June 30, 2017		2,923,114		$	3.00

Stock options

A summary of the Company’s stock option activity for the three months ended June 30, 2017 is as follows:

	Options Outstanding			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2017		10,956,201		$	4.63	$	4,876,437
Options granted		2,106,812		$	2.73	$	—
Options canceled / forfeited		(160,464	)	$	4.50	$	—
Options exercised		—		$	—	$	—
Outstanding at June 30, 2017		12,902,549		$	4.32	$	3,210,430
Vested and Exercisable at June 30, 2017		7,420,483		$	4.69	$	3,017,444

The weighted-average remaining contractual term of options exercisable and outstanding at June 30, 2017 was approximately 5.61 years.

Employee Stock Purchase Plan

Warrants

During the three months ended June 30, 2017 and June 30, 2016, there were no warrant exercises.

The following table summarizes warrant activity for the three months ended June 30, 2017:

	Warrants		Weighted- Average Exercise Price
Balance at March 31, 2017		221,370	$	7.16
Granted		—	$	—
Exercised		—	$	—
Cancelled		—	$	—
Balance at June 30, 2017		221,370	$	7.16

The warrants outstanding at June 30, 2017 are exercisable at prices between $2.28 and $7.62 per share, and have a weighted average remaining term of approximately 1.61 years.

Common stock reserved for future issuance

Common stock reserved for future issuance consisted of the following at June 30, 2017:

Common stock warrants outstanding			221,370
Common stock options outstanding under the 2008 Plan			622,192
Common stock options outstanding and reserved under the 2012 Plan			12,170,174
Common stock reserved under the 2016 Employee Stock Purchase Plan			1,447,443
Restricted stock units outstanding under the 2012 Plan			2,923,114
Common stock options outstanding and reserved under the Inducement Awards			2,088,212
Restricted stock units outstanding under the Inducement Awards			208,822
Total at June 30, 2017			19,681,327

XML 18 R8.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Jun. 30, 2017

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 3. Commitments and Contingencies

Operating leases

The Company leases laboratory and office space in San Diego, California under three non-cancelable leases as described below.

Rent expense was approximately $366,000 and $303,000 for the three months ended June 30, 2017 and 2016, respectively.

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2017, are as follows (in thousands):

Fiscal year ended March 31, 2018	$	1,196
Fiscal year ended March 31, 2019		1,465
Fiscal year ended March 31, 2020		1,073
Fiscal year ended March 31, 2021		1,104
Fiscal year ended March 31, 2022		468
Thereafter		—
Total	$	5,306

Legal Matters

XML 19 R9.htm IDEA: XBRL DOCUMENT

Concentrations	3 Months Ended
Concentrations	Jun. 30, 2017
Risks And Uncertainties [Abstract]
Concentrations	Note 4. Concentrations Credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions primarily located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company has not experienced losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents. The Company is also potentially subject to concentrations of credit risk in its revenues and accounts receivable. Because it is in the early commercial stage, the Company’s revenues to date have been derived from a relatively small number of customers and collaborators. However, the Company has not historically experienced any accounts receivable write-downs and management does not believe significant credit risk exists as of June 30, 2017.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements	3 Months Ended
Recent Accounting Pronouncements	Jun. 30, 2017
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Pronouncements	Note 5. Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard was originally effective for public companies for annual reporting periods beginning after December 15, 2016, with no early application permitted. In August 2015, the FASB issued ASU No. 2015-14 that defers by one year the effective date for all entities, with application permitted as of the original effective date. The updated standard becomes effective for us on April 1, 2018, with early adoption permitted as of April 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that this update will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of this updated standard on our ongoing financial reporting. We do not have plans to adopt this standard prior to the effective date. In February 2016, the FASB issued ASU 2016-02, Leases, which requires an entity to recognize lease assets and lease liabilities on the balance sheet for leases with terms of more than 12 months and to disclose key information about leasing arrangements. This new guidance is effective for us on April 1, 2019, with early adoption permitted in any interim or annual period. The Company is currently evaluating the impact that this guidance will have on its financial statements and related disclosures. In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718), which requires an entity recognize excess tax benefits and deficiencies as income tax expense or benefit, the cash flows of which should be included as operating activity in the statement of cash flows. An entity is allowed to either continue accruing compensation cost based on expected forfeitures or to begin recognizing expense as forfeitures occur. In addition, an entity may withhold the maximum statutory tax, increasing the allowable cash settlement portion of awards. The cash paid by an employer when directly withholding shares for tax purposes should be included in the financing activity section of the statement of cash flows. This new guidance became effective for us on April 1, 2017. The requirements of ASU 2016-09 did not have a significant impact on our consolidated financial statements.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Subsequent Events	3 Months Ended
Subsequent Events	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 6. Subsequent Events During July 2017, the Company issued 398,728 shares of its common stock pursuant to its at-the-market (“ATM”) facility for net proceeds exceeding $1.0 million.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Description of Business and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Nature of Operations and Basis of Presentation	Nature of operations and basis of presentation References in these notes to the unaudited condensed consolidated financial statements to “Organovo Holdings, Inc.,” “Organovo Holdings,” “we,” “us,” “our,” “the Company” and “our Company” refer to Organovo Holdings, Inc. and its consolidated subsidiaries. Our consolidated financial statements include the accounts of the Company as well as its wholly-owned subsidiaries, with all material intercompany accounts and transactions eliminated in consolidation. In December 2014, we established a wholly-owned subsidiary, Samsara Sciences, Inc., to focus on the acquisition of qualified cells in support of our commercial and research endeavors. In September 2015, we established another wholly-owned subsidiary in the United Kingdom, Organovo U.K., Ltd., for the primary purpose of establishing a sales presence in Europe. Since its inception, the Company has devoted its efforts primarily to developing and commercializing a platform technology and functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company has also focused efforts on raising capital and building infrastructure. In November 2014, the Company announced the commercial release of its first product, the ExVive™ Human Liver Tissue for use in toxicology and other preclinical drug testing. In September 2016, the Company announced that it had begun commercial contracting for services relating to its second product, the ExVive™ Human Kidney tissue. The Company’s activities are subject to significant risks and uncertainties including failing to successfully develop products and services based on its technology and to achieve the market acceptance necessary to generate sufficient revenues to support its operations and to achieve and sustain profitability. The accompanying interim condensed consolidated financial statements have been prepared by the Company, without audit, in accordance with the instructions to Form 10-Q and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of its financial position, results of operations, stockholders’ equity and cash flows in accordance with generally accepted accounting principles (“GAAP”). The balance sheet at March 31, 2017 is derived from the Company’s audited balance sheet at that date. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These financial statements should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2017, filed with the Securities and Exchange Commission (the “SEC”) on June 7, 2017. Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2018.
Liquidity	Liquidity As of June 30, 2017, the Company had cash and cash equivalents of approximately $55.0 million and an accumulated deficit of approximately $209.4 million. The Company also had negative cash flows from operations of approximately $10.7 million during the three months ended June 30, 2017. Through June 30, 2017, the Company has financed its operations primarily through the sale of convertible notes, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative research agreements, grants, and licenses. During the quarter ended June 30, 2017, the Company issued 1,139,489 shares of its common stock through its ATM facility and received net proceeds of approximately $3.0 million. On October 25, 2016, the Company closed the issuance and sale of 10,065,000 shares of its common stock in an underwritten public offering. The Company received net proceeds of approximately $25.7 million in the offering, after deducting underwriting discounts and commissions and the Company’s expenses. Based on its current operating plan and available cash resources, the Company has sufficient resources to fund its business for at least the next twelve months from the financial statement issuance date. The Company will need additional capital to further fund the development and commercialization of its human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or diseased tissues and organs. The Company intends to cover its future operating expenses through cash on hand, through revenue derived from research service agreements, product sales, collaborative research agreements, grants and royalty payments, and through the issuance of additional equity or debt securities. Depending on market conditions, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. Having insufficient funds may require us to delay, scale back, or eliminate some or all of our development programs or relinquish rights to our technology on less favorable terms than we would otherwise choose. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.
Use of estimates	Use of estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the condensed consolidated financial statements include those assumed in revenue recognized under the proportional performance model, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets.
Fair value measurement	Fair value measurement The Company had issued warrants, of which some were classified as derivative liabilities as a result of the terms in the warrants that provide for down-round protection in the event of a dilutive issuance. The Company used Level 3 inputs (unobservable inputs that are supported by little or no market activity, and that are significant to the fair value of the assets or liabilities) for its valuation methodology for the warrant derivative liabilities. The estimated fair values were determined using a Monte Carlo option pricing model based on various assumptions. The Company’s derivative liabilities were adjusted to reflect estimated fair value at each period end, with any increase or decrease in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of the derivative liabilities. Various factors are considered in the pricing models the Company used to value the warrants, including the Company’s current stock price, the remaining life of the warrant, the volatility of the Company’s stock price, and the risk-free interest rate. The remaining warrants expired as of March 31, 2017 and were removed from the Balance Sheet. The Company does not have any financial assets or liabilities measured on a fair value basis as of June 30, 2017 or March 31, 2017.
Revenue recognition	Revenue recognition The Company’s revenues are derived from research service agreements, product sales, collaborative research agreements, grants and license- payments from the National Institutes of Health (“NIH”), U.S. Treasury Department, academic institutions, and private not-for-profit organizations. The Company recognizes revenue when the following criteria have been met: (i) persuasive evidence of an arrangement exists; (ii) services have been rendered or product has been delivered; (iii) price to the customer is fixed and determinable; and (iv) collection of the underlying receivable is reasonably assured. Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of June 30, 2017 and March 31, 2017, the Company had approximately $903,000 and $640,000, respectively, in deferred revenue related to its grants and royalty payments, collaborative research programs and research service agreements.
Revenue arrangements with multiple deliverables	Revenue arrangements with multiple deliverables The Company follows ASC 605-25 Revenue Recognition – Multiple-Element Arrangements for revenue arrangements that contain multiple deliverables. Judgment is required to properly identify the accounting units of the multiple deliverable transactions and to determine the manner in which revenue should be allocated among the accounting units. Moreover, judgment is used in interpreting the commercial terms and determining when all criteria of revenue recognition have been met for each deliverable in order for revenue recognition to occur in the appropriate accounting period. For multiple deliverable agreements, consideration is allocated at the inception of the agreement to all deliverables based on their relative selling price. The relative selling price for each deliverable is determined using vendor-specific objective evidence (“VSOE”) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, the Company uses its best estimate of the selling price for the deliverable. While changes in the allocation of the arrangement consideration between the units of accounting will not affect the amount of total revenue recognized for a particular sales arrangement, any material changes in these allocations could impact the timing of revenue recognition, which could affect the Company’s results of operations. The Company periodically receives license fees for non-exclusive research licensing associated with funded research projects. License fees under these arrangements are recognized over the term of the contract or development period as it has been determined that such licenses do not have stand-alone value.
Revenue from research service agreements	Revenue from research service agreements For research service agreements that contain only a single or primary deliverable, the Company defers any up-front fees collected from customers, and recognizes revenue for the delivered element only when it determines there are no uncertainties regarding customer acceptance. For agreements that contain multiple deliverables, the Company follows ASC 605-25 as described above.
Research and development revenue under collaborative agreements	Research and development revenue under collaborative agreements The Company’s collaboration revenue consists of license and collaboration agreements that contain multiple elements, which may include non-refundable up-front fees, payments for reimbursement of third-party research costs, payments for ongoing research, payments associated with achieving specific development milestones and royalties based on specified percentages of net product sales, if any. The Company considers a variety of factors in determining the appropriate method of revenue recognition under these arrangements, such as whether the elements are separable, whether there are determinable fair values and whether there is a unique earnings process associated with each element of a contract. The Company recognizes revenue from research funding under collaboration agreements when earned on a “proportional performance” basis as research services are provided or substantive milestones are achieved. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to us for the milestone (i) is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance, (ii) relates solely to our past performance and (iii) is reasonable relative to all of the other deliverables and payments within the arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the risks that must be overcome to achieve the milestone, the level of effort and investment required to achieve the milestone and whether any portion of the milestone consideration is related to future performance or deliverables. The Company initially defers revenue for any amounts billed or payments received in advance of the services being performed, and recognizes revenue pursuant to the related pattern of performance, using the appropriate method of revenue recognition based on its analysis of the related contractual element(s). In November 2014, the Company entered into a collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter at the university for the purpose of developing bioprinted tissues for surgical transplantation research. The Company has recorded $0 and $12,500 for the three months ended June 30, 2017 and 2016, respectively, in revenue related to this collaboration in recognition of the proportional performance achieved. In April 2015, the Company entered into a research collaboration agreement with a third party to develop custom tissue models for fixed fees. Based on the proportional performance achieved under this agreement, no collaboration revenue was recorded for the three months ended June 30, 2017 or 2016. Also in April 2015, the Company entered into a multi-year research agreement with a third party to develop multiple custom tissue models for use in drug development. Approximately $0 and $200,000 were recorded as revenue in recognition of the proportional performance achieved under this agreement during the three months ended June 30, 2017 and 2016, respectively. In June 2016, the Company announced it had entered into another collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter at the university for the purpose of developing bioprinted tissues for skeletal disease research. The Company received an up-front payment in June 2016, which was initially been recorded as deferred revenue. Revenue of $17,000 and $0 has been recorded under this agreement during the three months ended June 30, 2017 and 2016, respectively. In December 2016, the Company signed another collaborative non-exclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter at the university for the purpose of developing an architecturally correct kidney for potential therapeutic applications. The Company received an up-front payment in January and March of 2017, which has been recorded as deferred revenue. Revenue of $10,000 has been recorded under this agreement for the three months ended June 30, 2017.
Product revenue	Product revenue The Company recognizes product revenue at the time of shipment to the customer, provided all other revenue recognition criteria have been met. As our commercial sales increase, we expect to establish a reserve for estimated product returns that will be recorded as a reduction to revenue. This reserve will be maintained to account for future return of products sold in the current period. The reserve will be reviewed quarterly and will be estimated based on an analysis of our historical experience related to product returns.
Grant revenue	Grant revenue During August 2013, the Company was awarded a research grant by a private, not-for-profit organization for up to $251,700, contingent on go/no-go decisions made by the grantor at the completion of each stage of research as outlined in the grant award. Revenues from the grant are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized when the Company incurs expenses that are related to the grant. Revenue recognized under this grant was approximately $0 and $4,000 for the three months ended June 30, 2017 and 2016, respectively. The Company has completed its obligations under this agreement as of June 30, 2017.
Cost of revenues	Cost of revenues The Company reported $0.3 million and $0.2 million in cost of revenues for the three months ended June 30, 2017 and 2016, respectively. This captures our costs related to manufacturing and delivering our product and service revenue.
Net loss per share	Net loss per share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three months ended June 30, 2017 and 2016, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Common stock equivalents excluded from computing diluted net loss per share were approximately 16.0 million for the three months ended June 30, 2017, and 11.6 million for the three months ended June 30, 2016.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Jun. 30, 2017

Equity [Abstract]

Schedule of Stock-based Compensation Expense

Stock-based compensation expense for all stock awards consists of the following (in thousands):

	Three Months Ended		Three Months Ended
	June 30, 2017		June 30, 2016
Research and development	$	331	$	408
General and administrative	$	1,721	$	1,021
Total	$	2,052	$	1,429

Fair Value of Employee Stock Options

The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

	Three Months Ended			Three Months Ended
	June 30, 2017			June 30, 2016
Dividend yield		—			—
Volatility		74.27	%		71.30	%
Risk-free interest rate		1.62	%		1.20	%
Expected life of options	6.00 years			6.00 years
Weighted average grant date fair value	$	1.79		$	2.03

Fair Value of Employee Stock Purchase Plan

The fair value of ESPP shares was estimated at the purchase period commencement date using the following weighted average assumptions:

	Three Months Ended
	June 30, 2017
Dividend yield		—
Volatility		74.70	%
Risk-free interest rate		0.79	%
Expected term	6 months
Weighted average grant date fair value	$	1.04

Summary of Company's Restricted Stock Unit Activity

A summary of the Company’s restricted stock unit activity from March 31, 2017 through June 30, 2017 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2017		1,178,114		$	3.57
Granted		1,862,078		$	2.66
Vested		(36,221	)	$	3.85
Canceled / forfeited		(80,857	)	$	3.21
Unvested at June 30, 2017		2,923,114		$	3.00

Summary of Stock Option Activity

A summary of the Company’s stock option activity for the three months ended June 30, 2017 is as follows:

	Options Outstanding			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2017		10,956,201		$	4.63	$	4,876,437
Options granted		2,106,812		$	2.73	$	—
Options canceled / forfeited		(160,464	)	$	4.50	$	—
Options exercised		—		$	—	$	—
Outstanding at June 30, 2017		12,902,549		$	4.32	$	3,210,430
Vested and Exercisable at June 30, 2017		7,420,483		$	4.69	$	3,017,444

Summary of Warrant Activity

The following table summarizes warrant activity for the three months ended June 30, 2017:

	Warrants		Weighted- Average Exercise Price
Balance at March 31, 2017		221,370	$	7.16
Granted		—	$	—
Exercised		—	$	—
Cancelled		—	$	—
Balance at June 30, 2017		221,370	$	7.16

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consisted of the following at June 30, 2017:

Common stock warrants outstanding			221,370
Common stock options outstanding under the 2008 Plan			622,192
Common stock options outstanding and reserved under the 2012 Plan			12,170,174
Common stock reserved under the 2016 Employee Stock Purchase Plan			1,447,443
Restricted stock units outstanding under the 2012 Plan			2,923,114
Common stock options outstanding and reserved under the Inducement Awards			2,088,212
Restricted stock units outstanding under the Inducement Awards			208,822
Total at June 30, 2017			19,681,327

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

3 Months Ended

Jun. 30, 2017

Commitments And Contingencies Disclosure [Abstract]

Future Minimum Rental Payments Required under Operating Leases that have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2017, are as follows (in thousands):

Fiscal year ended March 31, 2018	$	1,196
Fiscal year ended March 31, 2019		1,465
Fiscal year ended March 31, 2020		1,073
Fiscal year ended March 31, 2021		1,104
Fiscal year ended March 31, 2022		468
Thereafter		—
Total	$	5,306

XML 25 R15.htm IDEA: XBRL DOCUMENT

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)			1 Months Ended	3 Months Ended
	Oct. 25, 2016	Oct. 20, 2016	Aug. 31, 2013	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents				$ 54,974,000	$ 53,538,000	$ 62,751,000		$ 62,091,000
Accumulated deficit				(209,419,000)		(199,317,000)
Cash flow from operations				$ 10,653,000	8,541,000
Issuance of common stock							105,724,320	104,551,466
Warrants expiration date				Mar. 31, 2017
Deferred revenue				$ 854,000		582,000
Revenue recognized under grants				0	4,000
Cost of revenues				301,000	168,000
Dilutive effect				$ 0	$ 0
Common stock equivalents excluded from computing diluted net loss per share				16,000,000	11,600,000
Private, Not-for-Profit Organization [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants				$ 0	$ 4,000
Maximum [Member] \| Private, Not-for-Profit Organization [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants			$ 251,700
Research and Development Services [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Deferred revenue				903,000		$ 640,000
Research and Development Services Six [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Revenue related to research contract				0	12,500
Research and Development Services Four [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Revenue related to research contract				0	0
Research and Development Services Five [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Revenue related to research contract				0	200,000
Research and Development Services Seven [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Revenue related to research contract				17,000	$ 0
Research and Development Services Eight [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Revenue related to research contract				$ 10,000
At-The-Market Facility [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Issuance of common stock				1,139,489
Gross proceeds from sale of common stock shares				$ 3,000,000
Over Allotment Option [Member] \| 2016 Underwriting Agreement [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Issuance of common stock	10,065,000
Secondary Offering [Member] \| 2016 Underwriting Agreement [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Gross proceeds from sale of common stock shares	$ 25,700,000	$ 25,700,000

XML 26 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 2,052	$ 1,429
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	331	408
General and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,721	$ 1,021

XML 27 R17.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail)	3 Months Ended
	Jun. 30, 2017 USD ($)
Class Of Stock [Line Items]
Total unrecognized compensation cost related to unvested stock option grants	$ 11,430,000
Employee Stock Purchase Plan [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	2 months
Unrecognized stock-based compensation expense	$ 21,500
Stock options [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	2 years 6 months 11 days
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	3 years 4 months 24 days
Unrecognized stock-based compensation expense	$ 7,814,000
Restricted stock [Member]
Class Of Stock [Line Items]
Unrecognized stock-based compensation expense	$ 0

XML 28 R18.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Fair Value of Employee Stock Options (Detail) - $ / shares	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Dividend yield	0.00%	0.00%
Volatility	74.27%	71.30%
Risk-free interest rate	1.62%	1.20%
Expected life of options	6 years	6 years
Weighted average grant date fair value	$ 1.79	$ 2.03

XML 29 R19.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) - $ / shares	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Volatility	74.27%	71.30%
Risk-free interest rate	1.62%	1.20%
Expected term	6 years	6 years
Weighted average grant date fair value	$ 1.79	$ 2.03
2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%
Volatility	74.70%
Risk-free interest rate	0.79%
Expected term	6 months
Weighted average grant date fair value	$ 1.04

XML 30 R20.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Preferred Stock - Additional Information (Detail)	Jun. 30, 2017 shares
Equity [Abstract]
Preferred stock, shares authorized	25,000,000
Preferred stock, shares outstanding	0

XML 31 R21.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Common Stock - Additional Information (Detail) - USD ($)						1 Months Ended	3 Months Ended		31 Months Ended
	Oct. 25, 2016	Oct. 20, 2016	Jul. 20, 2016	Jun. 23, 2015	Jul. 17, 2013	Dec. 31, 2014	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Apr. 24, 2017	Dec. 31, 2016	Mar. 31, 2016	Aug. 31, 2015	Feb. 27, 2015	Aug. 31, 2013	Jan. 31, 2012	May 31, 2008
Class Of Stock [Line Items]
Common stock reserved for future issuance							19,681,327		19,681,327
Issuance of common stock from stock options exercises, net, Shares							0	0
Issuance of common stock											105,724,320	104,551,466
Issuance of common stock from warrant exercises, net, Shares							0	0
Equity Offering Sales Agreement [Member]
Class Of Stock [Line Items]
Common stock reserved for future issuance			26,600,000
Equity sales agreement expiration date			Mar. 17, 2018
Issuance of common stock from stock options exercises, net, Shares							1,139,489	0
Value of shares sold under equity distribution agreement							$ 3,000,000	$ 0	$ 13,700,000
Issuance of common stock							3,136,670		3,136,670
Additional common stocks under shelf registration							$ 18,800,000		$ 18,800,000
Maximum [Member] \| Equity Distribution Agreement [Member]
Class Of Stock [Line Items]
Number of shares to be offered and sold in equity distribution agreement						30,000,000
IPO [Member]
Class Of Stock [Line Items]
Securities authorized for offer and sale, amount					$ 100,000,000									$ 190,000,000
Stock securities distribution plan expiration year					2016
Secondary Offering [Member] \| 2015 Underwriting Agreement [Member]
Class Of Stock [Line Items]
Issuance of common stock from stock options exercises, net, Shares				10,838,750
Offering price per share				$ 4.25
Gross proceeds from sale of common stock shares				$ 43,100,000
Secondary Offering [Member] \| 2016 Underwriting Agreement [Member]
Class Of Stock [Line Items]
Offering price per share		$ 2.75
Gross proceeds from sale of common stock shares	$ 25,700,000	$ 25,700,000
Over Allotment Option [Member] \| 2015 Underwriting Agreement [Member]
Class Of Stock [Line Items]
Sale of stock price per share net of fees				$ 3.995
Over Allotment Option [Member] \| 2016 Underwriting Agreement [Member]
Class Of Stock [Line Items]
Issuance of common stock	10,065,000
Sale of stock price per share net of fees		$ 2.585
Equity Incentive Plan 2008 [Member]
Class Of Stock [Line Items]
Common shares authorized to be issued																	1,521,584
Termination date of equity incentive plan							Jul. 01, 2018
Shares issued during the year							0
Equity Incentive Plan 2012 [Member]
Class Of Stock [Line Items]
Common shares authorized to be issued													6,000,000		5,000,000	6,553,986
Shares available for issuance							1,978,029		1,978,029				17,553,986
Termination period of Equity Incentive Plan							10 years
Inducement Award Agreements [Member]
Class Of Stock [Line Items]
Common shares authorized to be issued										2,297,034

XML 32 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Restricted Stock Awards and Restricted Stock Units - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Apr. 24, 2017	Mar. 31, 2017
Restricted stock [Member]
Class Of Stock [Line Items]
Restricted stock surrendered	0	2,259
Restricted stock awards vested during the period	0	6,250
Stock option granted with immediate vesting	0	2,259
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Restricted stock awards vested during the period	36,221
Restricted stock awards granted	1,862,078
Award vesting conditions	Vesting generally occurs (i) on the one-year anniversary of the grant date, (ii) quarterly over a three-year period, (iii) quarterly over a four-year period, (iv) over a four-year period, with 25% vesting on the one-year anniversary of the vesting commencement date and the remainder vesting ratably on a quarterly basis over the next twelve quarters, or (v) over a three-year period with 50% vesting on the two-year anniversary of the vesting commencement date and 50% vesting on the three-year anniversary of the vesting commencement date.
Period for vesting schedule over start date	4 years
Awards granted remainder vesting period ratably on a quarterly basis	36 months
Award vesting percentage on the two-year anniversary	50.00%
Award vesting percentage on the three-year anniversary	50.00%
Number of shares allocated	2,923,114			1,178,114
Restricted stock units (RSUs) [Member] \| Yearly Vesting [Member]
Class Of Stock [Line Items]
Award vesting percentage	25.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| CEO [Member]
Class Of Stock [Line Items]
Number of shares allocated			208,822
Expense recognized during period	$ 0

XML 33 R23.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Company's Restricted Stock Unit Activity (Detail) - Restricted stock units (RSUs) [Member]	3 Months Ended
	Jun. 30, 2017 $ / shares shares
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares \| shares	1,178,114
Granted, Number of Shares \| shares	1,862,078
Vested, Number of Shares \| shares	(36,221)
Canceled / forfeited, Number of Shares \| shares	(80,857)
Ending balance, Unvested, Number of Shares \| shares	2,923,114
Beginning balance, Unvested, Weighted Average Price \| $ / shares	$ 3.57
Granted, Weighted Average Price \| $ / shares	2.66
Vested, Weighted Average Price \| $ / shares	3.85
Canceled / forfeited, Weighted Average Price \| $ / shares	3.21
Ending balance, Unvested, Weighted Average Price \| $ / shares	$ 3.00

XML 34 R24.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) - USD ($)		3 Months Ended
	Apr. 24, 2017	Jun. 30, 2017	Jun. 30, 2016
Class Of Stock [Line Items]
Issuances of common stock from stock option exercises, Shares		0
Weighted-average remaining contractual term of options exercisable		5 years 7 months 10 days
Weighted-average remaining contractual term of options outstanding		5 years 7 months 10 days
Number of common stock shares approved under ESPP		19,681,327
Expected life of options		6 years	6 years
2012 Plan [Member]
Class Of Stock [Line Items]
Issuances of common stock from stock option exercises, Shares		18,600	416,640
Remaining options vest		36 months
Inducement Award Agreements [Member] \| CEO [Member]
Class Of Stock [Line Items]
Stock options granted	2,088,212
2016 Employee Stock Purchase Plan [Member]
Class Of Stock [Line Items]
Number of common stock shares approved under ESPP		1,500,000
Employee subscription rate		15.00%
Compensation amount per employee		$ 25,000
Number of shares per employee		10,000
Fair market value at discount		85.00%
Purchase period		6 months
Initial offering period		2016-09
Description of plan		Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period.
Expected life of options		6 months
Shares available for issuance		1,447,443
Stock options [Member] \| 2012 Plan [Member]
Class Of Stock [Line Items]
Award vesting conditions		stock options generally vest (i) on the one-year anniversary of the grant date, (ii) quarterly over a three-year period, or (iii) over a four-year period with a quarter vesting on either the one year anniversary of employment or the one year anniversary of the vesting commencement date
Stock options [Member] \| Inducement Award Agreements [Member]
Class Of Stock [Line Items]
Number of common stock shares approved under ESPP		2,088,212
Stock options [Member] \| Inducement Award Agreements [Member] \| CEO [Member]
Class Of Stock [Line Items]
Award vesting conditions		These stock options vest over a four-year period with a quarter vesting on either the one year anniversary of employment or the one year anniversary of the vesting commencement date.
Period for vesting schedule over start date	4 years
Stock options [Member] \| 2016 Employee Stock Purchase Plan [Member]
Class Of Stock [Line Items]
Number of common stock shares approved under ESPP		1,447,443

XML 35 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Stock Option Activity (Detail)	3 Months Ended
	Jun. 30, 2017 USD ($) $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Outstanding, Beginning balance \| shares	10,956,201
Granted, Options Outstanding \| shares	2,106,812
Canceled / forfeited, Options Outstanding \| shares	(160,464)
Exercised, Options Outstanding \| shares	0
Options Outstanding, Ending balance \| shares	12,902,549
Vested and Exercisable, Options Outstanding \| shares	7,420,483
Weighted-Average Exercise Price, Options Beginning balance \| $ / shares	$ 4.63
Options granted, Weighted-Average Exercise Price \| $ / shares	2.73
Options canceled / forfeited, Weighted-Average Exercise Price \| $ / shares	4.50
Options exercised, Weighted-Average Exercise Price \| $ / shares	0
Weighted-Average Exercise Price, Options Ending balance \| $ / shares	4.32
Vested and Exercisable, Weighted-Average Exercise Price \| $ / shares	$ 4.69
Aggregate Intrinsic Value, Options Beginning balance \| $	$ 4,876,437
Options Exercised, Aggregate Intrinsic Value \| $	0
Aggregate Intrinsic Value, Options \| $	3,210,430
Vested and Exercisable, Aggregate Intrinsic Value \| $	$ 3,017,444

XML 36 R26.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Warrants - Additional Information (Detail) - $ / shares	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Class Of Stock [Line Items]
Weighted-average remaining contractual term of options exercisable	5 years 7 months 10 days
Minimum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share	$ 2.28
Maximum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share	$ 7.62
Warrants [Member]
Class Of Stock [Line Items]
Number of warrants exercised	0	0
Weighted-average remaining contractual term of options exercisable	1 year 7 months 10 days

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Warrant Activity (Detail)	3 Months Ended
	Jun. 30, 2017 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance \| shares	10,956,201
Granted, Options Outstanding \| shares	2,106,812
Exercised, Options Outstanding \| shares	0
Options Outstanding, Ending balance \| shares	12,902,549
Weighted-Average Exercise Price, Options Beginning balance \| $ / shares	$ 4.63
Granted, Weighted-Average Exercise Price \| $ / shares	2.73
Exercised, Weighted-Average Exercise Price \| $ / shares	0
Weighted-Average Exercise Price, Options Ending balance \| $ / shares	$ 4.32
Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance \| shares	221,370
Granted, Options Outstanding \| shares	0
Exercised, Options Outstanding \| shares	0
Cancelled, Options Outstanding \| shares	0
Options Outstanding, Ending balance \| shares	221,370
Weighted-Average Exercise Price, Options Beginning balance \| $ / shares	$ 7.16
Granted, Weighted-Average Exercise Price \| $ / shares	0
Exercised, Weighted-Average Exercise Price \| $ / shares	0
Cancelled, Weighted-Average Exercise Price \| $ / shares	0
Weighted-Average Exercise Price, Options Ending balance \| $ / shares	$ 7.16

XML 38 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail)	Jun. 30, 2017 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	19,681,327
2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	1,500,000
Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	221,370
Stock options [Member] \| Equity Incentive Plan 2008 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	622,192
Stock options [Member] \| Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	12,170,174
Stock options [Member] \| 2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	1,447,443
Stock options [Member] \| Inducement Award Agreements [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	2,088,212
Restricted stock units (RSUs) [Member] \| Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	2,923,114
Restricted stock units (RSUs) [Member] \| Inducement Award Agreements [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	208,822

XML 39 R29.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail)			3 Months Ended		60 Months Ended
	Dec. 28, 2015 USD ($) ft²	Jan. 09, 2015 USD ($) ft²	Jun. 30, 2017 USD ($) ft² Lease	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) Lease
Commitments And Contingencies [Line Items]
Number of non-cancelable leases \| Lease			3		3
Rent expense per month			$ 120,000
Base rent escalators		3.00%	3.00%		3.00%
Office space under lease agreement \| ft²			45,580
Area of leased office space \| ft²	12,088	5,803
Lease term		36 months
Lease rental period start date	Feb. 01, 2016	Feb. 01, 2015
Lease rental period end date	Jan. 31, 2017	Jan. 31, 2018
Base rent under the lease	$ 15,000	$ 12,000
Leasehold improvements					$ 518,000
Rent expense			$ 366,000	$ 303,000
Lease Term For Remainder of Rentable Square Footage [Member]
Commitments And Contingencies [Line Items]
Lease expiration date			Sep. 01, 2021
Lease option termination description			option to terminate this lease on or after September 1, 2019
Lease Term For 14,685 of Total Rentable Square Footage [Member]
Commitments And Contingencies [Line Items]
Office space under lease agreement \| ft²			14,685
Lease expiration date			Dec. 15, 2018

XML 40 R30.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Future Minimum Rental Payments Required under Operating Leases that have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year (Detail) $ in Thousands	Jun. 30, 2017 USD ($)
Commitments And Contingencies Disclosure [Abstract]
Fiscal year ended March 31, 2018	$ 1,196
Fiscal year ended March 31, 2019	1,465
Fiscal year ended March 31, 2020	1,073
Fiscal year ended March 31, 2021	1,104
Fiscal year ended March 31, 2022	468
Thereafter	0
Total	$ 5,306

XML 41 R31.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended
	Jul. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Mar. 31, 2016
Subsequent Event [Line Items]
Issuance of common stock			105,724,320	104,551,466
At-The-Market Facility [Member]
Subsequent Event [Line Items]
Issuance of common stock		1,139,489
Subsequent Event [Member] \| At-The-Market Facility [Member]
Subsequent Event [Line Items]
Issuance of common stock	398,728
Subsequent Event [Member] \| At-The-Market Facility [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Net proceeds from sale of common stock	$ 1.0

EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 43 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 95 201 1 false 35 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.organovo.com/20170630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.organovo.com/20170630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.organovo.com/20170630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss Sheet http://www.organovo.com/20170630/taxonomy/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveLoss Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://www.organovo.com/20170630/taxonomy/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows Unaudited Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 100050 - Disclosure - Description of Business and Summary of Significant Accounting Policies Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies Description of Business and Summary of Significant Accounting Policies Notes 6 false false R7.htm 100060 - Disclosure - Stockholders' Equity Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 7 false false R8.htm 100070 - Disclosure - Commitments and Contingencies Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 8 false false R9.htm 100080 - Disclosure - Concentrations Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureConcentrations Concentrations Notes 9 false false R10.htm 100090 - Disclosure - Recent Accounting Pronouncements Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 10 false false R11.htm 100100 - Disclosure - Subsequent Events Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 11 false false R12.htm 100110 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies Description of Business and Summary of Significant Accounting Policies (Policies) Policies http://www.organovo.com/20170630/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies 12 false false R13.htm 100120 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquity 13 false false R14.htm 100130 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.organovo.com/20170630/taxonomy/role/DisclosureCommitmentsAndContingencies 14 false false R15.htm 100140 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) Details 15 false false R16.htm 100150 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetail Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) Details 16 false false R17.htm 100160 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseAndValuationInformationAdditionalInformationDetail Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail) Details 17 false false R18.htm 100170 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Options (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquityFairValueOfEmployeeStockOptionsDetail Stockholders' Equity - Fair Value of Employee Stock Options (Detail) Details 18 false false R19.htm 100180 - Disclosure - Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquityFairValueOfEmployeeStockPurchasePlanDetail Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) Details 19 false false R20.htm 100190 - Disclosure - Stockholders' Equity - Preferred Stock - Additional Information (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquityPreferredStockAdditionalInformationDetail Stockholders' Equity - Preferred Stock - Additional Information (Detail) Details 20 false false R21.htm 100200 - Disclosure - Stockholders' Equity - Common Stock - Additional Information (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquityCommonStockAdditionalInformationDetail Stockholders' Equity - Common Stock - Additional Information (Detail) Details 21 false false R22.htm 100210 - Disclosure - Stockholders' Equity - Restricted Stock Awards and Restricted Stock Units - Additional Information (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsAdditionalInformationDetail Stockholders' Equity - Restricted Stock Awards and Restricted Stock Units - Additional Information (Detail) Details 22 false false R23.htm 100220 - Disclosure - Stockholders' Equity - Summary of Company's Restricted Stock Unit Activity (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanySRestrictedStockUnitActivityDetail Stockholders' Equity - Summary of Company's Restricted Stock Unit Activity (Detail) Details 23 false false R24.htm 100230 - Disclosure - Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquityStockOptionsAndEmployeeStockPurchasePlanAdditionalInformationDetail Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) Details 24 false false R25.htm 100240 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail Stockholders' Equity - Summary of Stock Option Activity (Detail) Details 25 false false R26.htm 100250 - Disclosure - Stockholders' Equity - Warrants - Additional Information (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquityWarrantsAdditionalInformationDetail Stockholders' Equity - Warrants - Additional Information (Detail) Details 26 false false R27.htm 100260 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityDetail Stockholders' Equity - Summary of Warrant Activity (Detail) Details 27 false false R28.htm 100270 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetail Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail) Details 28 false false R29.htm 100280 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 29 false false R30.htm 100290 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments Required under Operating Leases that have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesThatHaveInitialOrRemainingNonCancelableLeaseTermsInExcessOfOneYearDetail Commitments and Contingencies - Future Minimum Rental Payments Required under Operating Leases that have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year (Detail) Details 30 false false R31.htm 100300 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.organovo.com/20170630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 31 false false All Reports Book All Reports onvo-20170630.xml onvo-20170630.xsd onvo-20170630_cal.xml onvo-20170630_def.xml onvo-20170630_lab.xml onvo-20170630_pre.xml true true ZIP 48 0001564590-17-016946-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-17-016946-xbrl.zip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end

Stockholders' Equity - Summary of Warrant Activity (Detail)	3 Months Ended
	Jun. 30, 2017 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance \| shares	10,956,201
Granted, Options Outstanding \| shares	2,106,812
Exercised, Options Outstanding \| shares	0
Options Outstanding, Ending balance \| shares	12,902,549
Weighted-Average Exercise Price, Options Beginning balance \| $ / shares	$ 4.63
Granted, Weighted-Average Exercise Price \| $ / shares	2.73
Exercised, Weighted-Average Exercise Price \| $ / shares	0
Weighted-Average Exercise Price, Options Ending balance \| $ / shares	$ 4.32
Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance \| shares	221,370
Granted, Options Outstanding \| shares	0
Exercised, Options Outstanding \| shares	0
Cancelled, Options Outstanding \| shares	0
Options Outstanding, Ending balance \| shares	221,370
Weighted-Average Exercise Price, Options Beginning balance \| $ / shares	$ 7.16
Granted, Weighted-Average Exercise Price \| $ / shares	0
Exercised, Weighted-Average Exercise Price \| $ / shares	0
Cancelled, Weighted-Average Exercise Price \| $ / shares	0
Weighted-Average Exercise Price, Options Ending balance \| $ / shares	$ 7.16